# 2026年1月8日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 胃癌：综述

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499132)
**期刊：** JAMA
**PMID：** 41499132
**DOI：** 10.1001/jama.2025.20034

### 第一部分 原文与翻译

**英文原标题：** Gastric Cancer: A Review.

> **英文摘要：**
> IMPORTANCE: Globally, 968 350 new cases and 659 853 deaths from gastric cancer were reported in 2022. In the US, 30 300 new cases and 10 780 deaths were estimated in 2025.
> 
> OBSERVATIONS: Gastric cancer is more common in men, and the median age at diagnosis is 68 years. Most gastric cancers (>90%) are adenocarcinomas. Worldwide, 85% of cases arise from the stomach body or antrum and 15% from the cardia. In the US, more than 90% of patients diagnosed with gastric cancer present with symptoms such as weight loss and abdominal pain. At presentation, approximately 13% have localized disease (limited to the stomach), 15% to 25% have locally advanced disease, defined as a tumor that has spread to regional lymph nodes, and 35% to 65% have metastatic disease. Helicobacter pylori infection is a treatable risk factor associated with 90% of gastric body and antrum cancers globally. Additional modifiable risk factors include smoking, alcohol, obesity, and salt intake. In countries with high incidence such as Japan and Korea, routine endoscopic screening beginning at age 40 years is associated with improved survival. Diagnosis is made by endoscopic biopsy. Patients with localized gastric cancer are treated with surgical resection and have a 5-year relative survival rate of 75% with treatment. Patients with more advanced-stage disease should receive gastrectomy, perioperative chemotherapy with 5-fluorouracil, oxaliplatin, and docetaxel and immunotherapy (durvalumab). Metastatic or unresectable disease may be treated with chemotherapy, immunotherapy, and/or targeted therapy depending on biomarkers, including programmed cell death ligand 1 (PD-L1), human epidermal growth factor receptor 2 (ERBB2; formerly HER2 or HER2/neu), and claudin-18, isoform 2 (CLDN18.2). For PD-L1-expressing gastric cancer, adding immune checkpoint inhibitors, such as nivolumab and pembrolizumab, is associated with an additional 3 months of survival when compared with chemotherapy alone. For gastric cancers overexpressing the ERBB2 or CLDN18.2 proteins, the addition of trastuzumab or zolbetuximab, respectively, is associated with an additional 3 to 4 months' survival. Early supportive care focusing on symptom management and on nutritional and psychosocial support is associated with 3 months of survival benefit. Less than 10% of patients with metastatic gastric cancer survive more than 5 years.
> 
> CONCLUSIONS AND RELEVANCE: Approximately 30 300 new cases of gastric cancer are diagnosed annually in the US. Localized gastric cancer is treated with gastrectomy, and locally advanced disease is treated with surgery and chemoimmunotherapy. For patients with unresectable or metastatic gastric cancer, chemotherapy with immune checkpoint inhibitors and targeted therapies such as trastuzumab or zolbetuximab improves survival by several months.

> **中文摘要：**
> 重要性：2022年全球报告了968,350例新发胃癌病例和659,853例死亡病例。在美国，预计2025年将有30,300例新病例和10,780例死亡。
> 
> 观察结果：胃癌在男性中更为常见，中位诊断年龄为68岁。大多数胃癌（>90%）为腺癌。全球范围内，约85%的病例源自胃体或幽门窦，15%源自贲门。在美国，超过90%的胃癌患者出现如体重减轻和腹痛等症状。就诊时，约13%的患者为局限性疾病（局限于胃内），15%至25%的患者为局部进展期疾病（定义为肿瘤已扩散至区域淋巴结），而35%至65%的患者为转移性疾病。幽门螺杆菌感染是一种可治疗的危险因素，全球约90%的胃体和幽门窦癌与其相关。其他可修正的风险因素包括吸烟、饮酒、肥胖和食盐摄入。在日本和韩国等高发国家，从40岁开始进行常规胃镜筛查与改善生存率相关。诊断依靠胃镜活检完成。局限性胃癌患者接受外科切除治疗，治疗后的5年相对生存率为75%。更晚期的患者应接受胃切除术、以5-氟尿嘧啶、奥沙利铂和多西他赛为基础的围手术期化疗以及免疫治疗（度伐利尤单抗）。对于转移性或不可切除性疾病，可根据生物标志物选择化疗、免疫治疗和/或靶向治疗，这些标志物包括程序性死亡配体1（PD-L1）、人表皮生长因子受体2（ERBB2；原HER2或HER2/neu）以及紧密连接蛋白-18.2同工型（CLDN18.2）。对于PD-L1阳性的胃癌，在化疗基础上加用免疫检查点抑制剂（如纳武利尤单抗或帕博利珠单抗）可使生存期延长约3个月。对于ERBB2或CLDN18.2蛋白高表达的胃癌，分别加用曲妥珠单抗或佐贝妥昔单抗可额外延长3至4个月的生存期。早期的支持治疗，侧重于症状管理、营养和心理社会支持，可带来约3个月的生存获益。少于10%的转移性胃癌患者可生存超过5年。
> 
> 结论与意义：美国每年约诊断30,300例新发胃癌。局限性胃癌以胃切除术为主，局部进展期疾病需联合手术与化免疗法。对于不可切除或转移性胃癌患者，联合免疫检查点抑制剂和靶向药物（如曲妥珠单抗或佐贝妥昔单抗）的化疗可延长数月生存期。

### 第二部分 AI 大师评价

该综述全面总结了胃癌的流行病学、危险因素、临床特征、诊断及治疗策略，强调了幽门螺杆菌感染和生活方式因素的重要性。文章整合了外科手术、化疗、免疫治疗及靶向药物的最新证据，展现出胃癌治疗的多学科协作趋势。其创新在于结合生物标志物指导治疗的精准化方向，但局限在于数据多来自北美、东亚等高发区域，仍需更多全球性验证。整体而言，本研究为临床医生提供了最新且系统的治疗决策依据。

---

## 2. DNA损伤反应缺陷是ESR1突变型乳腺癌中的可靶向治疗弱点

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499130)
**期刊：** Cancer research
**PMID：** 41499130
**DOI：** 10.1158/0008-5472.CAN-24-3891

### 第一部分 原文与翻译

**英文原标题：** Defective DNA Damage Response is a Targetable Therapeutic Vulnerability in ESR1 Mutant Breast Cancer.

> **英文摘要：**
> ESR1 mutations are the leading cause of endocrine therapy resistance and progression in ER-positive metastatic breast cancer. ESR1 mutations are detected in ~50% of metastatic breast cancer patients, and identification of effective targeted therapeutics are critically needed. Here, we identified enrichment of dysregulated replication stress and DNA damage responses in multiple ESR1 mutant models. Targeting the replication stress response utilizing checkpoint inhibition in combination with PARP inhibition synergistically suppressed growth, induced cell cycle arrest, and attenuated DNA replication. PARP inhibition blocked metastatic dissemination in vivo and reduced both PARP1 and ER-regulated protein expression. PARP trapping by olaparib treatment with or without endocrine therapy resulted in a significant increase of co-localized DNA-bound PARP1 and ER protein in ESR1 mutant cells, indicating ER-PARP1 co-regulation in ESR1 mutant breast cancer. Long-term treatment with endocrine therapy plus the CDK4/6 inhibitor abemaciclib led to the emergence of a Y537S ESR1 mutation in a cell line, which exhibited dysregulation of replication stress response, enhanced DNA damage response, and synergistic responses to inhibitors of these pathways. PARP inhibition also synergized with clinically relevant endocrine therapy in ESR1 mutant models, reducing tumor growth both ex vivo and in vivo. Together, these results identify replication stress and DNA damage responses as key dysregulated pathways in ESR1 mutant breast cancer with significant clinical potential for PARP inhibition in this metastatic breast cancer subset.

> **中文摘要：**
> ESR1 突变是雌激素受体（ER）阳性转移性乳腺癌中导致内分泌治疗耐药和疾病进展的主要原因。在约 50% 的转移性乳腺癌患者中可检测到 ESR1 突变，因此迫切需要确定有效的靶向治疗方案。在本研究中，我们在多种 ESR1 突变模型中发现了复制应激与 DNA 损伤反应失调的富集。通过靶向复制应激反应，结合检查点抑制与 PARP 抑制的策略，协同抑制了细胞生长，诱导细胞周期阻滞，并减弱了 DNA 复制。PARP 抑制在体内阻断了转移扩散，并降低了 PARP1 和雌激素受体调控蛋白的表达。奥拉帕利治疗（无论是否联合内分泌治疗）导致 ESR1 突变细胞中 DNA 结合的 PARP1 与 ER 蛋白共定位显著增加，提示 ESR1 突变型乳腺癌中存在 ER 与 PARP1 的协同调控。长期给予内分泌治疗联合 CDK4/6 抑制剂阿贝西利后，一个细胞系出现了 Y537S ESR1 突变，该突变表现出复制应激反应失调、DNA 损伤反应增强，并对这些通路的抑制剂产生协同反应。PARP 抑制还与临床相关的内分泌疗法在 ESR1 突变模型中表现出协同作用，在离体和体内均可抑制肿瘤生长。综上所述，这些结果表明，复制应激和 DNA 损伤反应是 ESR1 突变型乳腺癌中关键的异常通路，且 PARP 抑制在这一转移性乳腺癌亚型中具有重要的临床应用潜力。

### 第二部分 AI 大师评价

该研究聚焦于 ESR1 突变导致的雌激素受体阳性转移性乳腺癌内分泌治疗耐药问题，系统分析了复制应激与 DNA 损伤反应的功能失调机制。作者通过多种 ESR1 突变模型发现 PARP 抑制与检查点阻断可协同抑癌，并揭示 ER 与 PARP1 的协同调控机制。研究结果不仅明确了复制应激信号通路的治疗潜力，也为 ESR1 突变型患者提供了靶向 PARP 治疗的新思路。其创新性在于将 DNA 修复失衡作为治疗突破口，但仍需进一步验证其临床转化有效性与安全性。

---

## 3. 利用靶向组织蛋白酶的猝灭型活性探针进行近红外成像以识别自然发生的犬四肢骨肉瘤

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498783)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41498783
**DOI：** 10.1158/1078-0432.CCR-25-2647

### 第一部分 原文与翻译

**英文原标题：** Near-Infrared Imaging Using a Cathepsin-Targeted, Quenched Activity-Based Probe Identifies Naturally Occurring Canine Appendicular Osteosarcoma.

> **英文摘要：**
> PURPOSE: Osteosarcoma is the most common primary malignancy of the skeleton. Despite advances in imaging modalities, neoadjuvant and adjuvant chemotherapy, and limb-sparing surgery over the past decades, there has been a general lack of improvement in survival rates. Tumor recurrence and metastases are associated with a worse prognosis, and complete tumor excision is critical. The use of real-time imaging could facilitate the acquisition of tumor-free surgical margins. Spontaneous osteosarcoma in dogs is an established translational model of human osteosarcoma.
> 
> PATIENTS AND METHODS: In this study, twelve dogs with spontaneous appendicular osteosarcoma received a cathepsin-targeted quenched activity-based probe (VGT-309) intravenously 16-20 hours before amputation. The limb was imaged at 4 levels of dissection, and the margins of near-infrared fluorescence were marked for comparison with histopathology and preoperative magnetic resonance imaging.
> 
> RESULTS: All appendicular tumors fluoresced on cross-section of the bone, and the extent of fluorescence coincided with MRI and histopathologic margins, with variability associated with necrosis. All tumors had visible fluorescence through cortical bone, although this did not consistently reflect intramedullary extension of tumor. Necrotic tumor regions did not fluoresce.
> 
> CONCLUSIONS: This data supports the safety and feasibility of VGT-309 as a tool for evaluating the tissue extent of canine osteosarcoma and spurs investigation for intraoperative detection of osteosarcoma during limb-sparing surgery in humans. Due to frequent intramedullary tumor extension and inconsistent fluorescence through unaffected cortical bone, this modality is likely most appropriate in assessing residual tumor following planned resection. Caution should be exercised when significant tumor necrosis is present.

> **中文摘要：**
> 研究目的：骨肉瘤是最常见的骨骼原发性恶性肿瘤。尽管影像学技术、新辅助和辅助化疗以及保肢手术在过去几十年中取得了进步，但总体生存率仍缺乏明显提高。肿瘤复发和转移与较差的预后有关，因此完全切除肿瘤至关重要。实时成像的应用可能有助于获得无肿瘤的手术切缘。犬自发性骨肉瘤是研究人类骨肉瘤的一个成熟转化模型。
> 
> 患者与方法：在本研究中，十二只自发性四肢骨肉瘤犬在截肢手术前16–20小时静脉注射一种靶向组织蛋白酶的猝灭型活性探针（VGT-309）。在解剖的四个层面进行肢体成像，并标记近红外荧光的边界以与组织病理学结果和术前磁共振成像进行比较。
> 
> 结果：所有四肢骨肿瘤在骨的横断面上均显示荧光，其荧光范围与MRI和组织病理学的切缘一致，但在坏死区域存在一定差异。所有肿瘤均可通过皮质骨观察到显著的荧光，但这种现象并不总是反映肿瘤的髓腔扩展。坏死的肿瘤区域未见荧光。
> 
> 结论：结果支持VGT-309作为评估犬骨肉瘤组织范围的安全且可行的工具，并为在人体保肢手术中术中检测骨肉瘤的研究提供了依据。由于髓腔内肿瘤常见扩展并且未受累皮质骨的荧光表现不一致，该成像方式最适合用于计划切除后评估残余肿瘤。当存在明显肿瘤坏死时，应谨慎解释成像结果。

### 第二部分 AI 大师评价

该研究验证了一种靶向组织蛋白酶的近红外探针（VGT-309）在犬自然发生性骨肉瘤中的成像能力。实验发现该探针能够清晰标识肿瘤范围并与MRI及组织学切缘高度一致，但坏死区域无荧光信号。结果表明VGT-309在术中实时判断肿瘤边界方面具有安全性和可行性，为人类保肢手术中的应用提供了潜在价值。然而，其在骨皮质荧光一致性和坏死组织成像方面仍存在局限，未来需进一步优化探针特性和应用策略。

---

## 4. 基于实时MRI监测的CRISPR-Cas9负载治疗诊断一体化脂质体，通过POLD4基因编辑增强前列腺癌放射增敏效应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498761)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41498761
**DOI：** 10.1002/advs.202519704

### 第一部分 原文与翻译

**英文原标题：** CRISPR-Cas9-Loaded Theranostic Liposomes for Enhancing Radiosensitization of Prostate Cancer through POLD4 Gene Editing under Real-Time MRI Monitoring.

> **英文摘要：**
> Radiotherapy is a fundamental treatment for prostate cancer; however, its therapeutic efficacy is frequently limited by radioresistance mediated through DNA repair mechanisms and other biological factors. Although gene therapy holds promise for overcoming such resistance, identifying effective radiosensitization targets and developing efficient gene delivery systems remain practically challenging. In this study, transcriptomic analysis of radiotherapy-treated prostate cancer cells revealed a marked upregulation of DNA polymerase delta subunit 4 (POLD4), a target that has not been systematically studied. To evaluate the potential of POLD4 for overcoming radioresistance, CRISPR-Cas9-based plasmids along with ultrasmall superparamagnetic iron oxide nanoparticles (USPIONs) were encapsulated within cationic liposomes for achieving an MRI-trackable gene delivery platform (plasmid and iron oxide co-loaded liposomes, termed PIO@Lipo). Comprehensive in vitro and in vivo studies demonstrated that PIO@Lipo enabled efficient POLD4 knockdown. Furthermore, PIO@Lipo synergized with radiotherapy to induce extensive DNA damage, promote tumor cell apoptosis, and remodel the immunosuppressive microenvironment. Notably, PIO@Lipo displayed superior MRI contrast enhancement capability and passive tumor targeting ability. In conclusion, this study has identified POLD4 as a potent target for radiosensitization, capable of disrupting DNA damage-repair homeostasis through MRI-monitored gene editing, thereby offering a promising strategy to enhance the efficacy of radiotherapy in prostate cancer.

> **中文摘要：**
> 放射治疗是前列腺癌的基本治疗手段；然而，其疗效常常受到由DNA修复机制及其他生物学因素介导的放射抗性所限制。尽管基因治疗有望克服此类抗性，但识别有效的放射增敏靶点并开发高效的基因递送系统仍是实际挑战。在本研究中，对接受放射治疗的前列腺癌细胞进行转录组分析，发现DNA聚合酶δ亚基4（POLD4）显著上调，而该靶点尚未被系统研究。为评估POLD4在克服放射抗性方面的潜力，研究者将基于CRISPR-Cas9的质粒与超小超顺磁性氧化铁纳米颗粒（USPIONs）共同封装于阳离子脂质体中，构建了一种可进行MRI追踪的基因递送平台（质粒与氧化铁共负载脂质体，称为PIO@Lipo）。系统的体外与体内研究表明，PIO@Lipo能够有效实现POLD4的下调。此外，PIO@Lipo与放射治疗协同作用，诱导广泛的DNA损伤，促进肿瘤细胞凋亡，并重塑免疫抑制性微环境。值得注意的是，PIO@Lipo表现出优异的MRI对比增强能力和被动肿瘤靶向性。综上所述，本研究确定了POLD4作为一种有效的放射增敏靶点，可通过MRI监测下的基因编辑破坏DNA损伤修复稳态，从而为提高前列腺癌放疗疗效提供了有前景的策略。

### 第二部分 AI 大师评价

本研究旨在通过CRISPR-Cas9介导的POLD4基因编辑，探讨克服前列腺癌放射抗性的策略。作者构建了可MRI追踪的纳米级治疗诊断一体化脂质体PIO@Lipo，实现了高效的基因递送与放疗协同效应。结果显示，该系统能显著增强DNA损伤和细胞凋亡，并改善肿瘤免疫微环境。创新点在于将基因编辑、分子影像监测与放疗敏化有机结合，但仍需进一步评估其临床转化的安全性与可控性。

---

## 5. 基于双适体的SETDB1 PROTAC作为乳腺癌有效抗肿瘤策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498743)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41498743
**DOI：** 10.1002/advs.202521159

### 第一部分 原文与翻译

**英文原标题：** Dual Aptamers-Based SETDB1 PROTACs as Effective Anti-Tumor Strategies for Breast Cancer.

> **英文摘要：**
> PROteolysis TArgeting Chimeras (PROTACs) have emerged as a promising strategy for drug development targeting oncogenic proteins. Here, we report the development and characterization of dual aptamer-based PROTACs targeting SET domain bifurcated histone lysine methyltransferase 1 (SETDB1), a key epigenetic regulator implicated in breast cancer progression, drug resistance, and tumor immune evasion. Using the Systematic Evolution of Ligands by Exponential Enrichment (SELEX) process, we identified a high-affinity single-stranded DNA (ssDNA) aptamer against SETDB1. This aptamer was conjugated to the nucleolin-targeting aptamer AS1411, generating a single-strand PROTAC (AP-SETDB1-S6A) and a partial double-strand PROTAC (AP-SETDB1-D2), both of which exhibit good serum stability. These two PROTACs directly penetrate breast cancer cells and effectively recruit the E3 ligase mouse double minute 2 homolog (MDM2) to SETDB1, inducing proteasome-dependent degradation of SETDB1. Functional assays demonstrated that both AP-SETDB1-S6A and AP-SETDB1-D2 significantly inhibit breast cancer cell proliferation and migration, and resensitize drug-resistant breast cancer cells to tamoxifen. Notably, they further enhance the cytotoxic activity of CD8 T cells against breast cancer cells and directly target breast cancer cells to suppress tumor growth in vivo. This study establishes dual aptamers-based PROTACs targeting SETDB1, offering effective therapeutic strategies for breast cancer treatment.

> **中文摘要：**
> 蛋白降解靶向嵌合体（PROTAC）已成为一种有前景的药物开发策略，用于针对致癌蛋白。本文报道了一种基于双适体的PROTAC的开发与特性分析，其靶向SET结构域分叉组蛋白赖氨酸甲基转移酶1（SETDB1）——一种参与乳腺癌进展、耐药形成和肿瘤免疫逃逸的关键表观遗传调控因子。通过配体的指数富集系统进化（SELEX）过程，研究人员鉴定出一种与SETDB1结合力高的单链DNA（ssDNA）适体。该适体与靶向核蛋白nucleolin的适体AS1411偶联，生成单链PROTAC（AP-SETDB1-S6A）和部分双链PROTAC（AP-SETDB1-D2），二者均表现出良好的血清稳定性。这两种PROTAC可直接穿透乳腺癌细胞，有效招募E3连接酶鼠双微体2同源物（MDM2）至SETDB1，从而诱导SETDB1的蛋白酶体依赖性降解。功能实验表明，AP-SETDB1-S6A和AP-SETDB1-D2均能显著抑制乳腺癌细胞的增殖与迁移，并使耐药乳腺癌细胞重新对他莫昔芬敏感。值得注意的是，它们还能增强CD8 T细胞对乳腺癌细胞的细胞毒活性，并在体内直接靶向乳腺癌细胞以抑制肿瘤生长。本研究建立了靶向SETDB1的双适体PROTAC体系，为乳腺癌治疗提供了有效的治疗新策略。

### 第二部分 AI 大师评价

本研究以SETDB1为靶点，设计出基于双适体的PROTAC分子，创新性地实现了精确靶向与高效降解相结合。研究采用SELEX筛选高亲和力适体，并利用AS1411实现肿瘤细胞特异性递送。实验结果展示了该体系在抑制肿瘤细胞生长、恢复药物敏感性及增强免疫杀伤中的显著作用。此策略为表观遗传靶点的精准降解提供了新方向，但其体内药代动力学和潜在免疫反应仍需进一步验证。

---

## 6. 内镜超声的新兴诊断适应证

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498716)
**期刊：** Gastroenterology
**PMID：** 41498716
**DOI：** 10.1053/j.gastro.2025.07.028

### 第一部分 原文与翻译

**英文原标题：** Emerging Diagnostic Indications for Endoscopic Ultrasound.

> **英文摘要：**
> Endoscopic ultrasound (EUS) has evolved from a diagnostic imaging tool into a versatile platform that enables high-precision access, sampling, and therapy across gastrointestinal and hepatobiliary diseases. This review summarizes recent advances that are reshaping diagnostic practice and theragnostics. In chronic pancreatitis, EUS remains central when cross-sectional imaging is equivocal; secretin-stimulated endoscopic pancreatic function testing can complement morphology, although discordant results limit standalone certainty. For pancreatic cancer, secretin-stimulated duodenal pancreatic-juice collection enables "liquid biopsy" analyses-including methylated DNA markers and extracellular-vesicle microRNAs-that augment carbohydrate antigen 19-9 and may enhance early detection and cyst surveillance. In endohepatology, EUS-guided portal pressure gradient measurement and liver biopsy offer accurate, same-session assessment with strong safety profiles. Adjunctive imaging-contrast-enhanced EUS and elastography-improves lesion characterization and targeting. Tissue acquisition has shifted toward end-cutting fine-needle biopsy needles, optimized by fanning/torque techniques, wet-suction, and macroscopic/visual on-site evaluation, reducing passes while preserving molecular adequacy. Artificial intelligence is emerging across workflows-from differentiating pancreatic lesions and staging to automating standardized photodocumentation and reporting-and is being explored for needle-based confocal laser endomicroscopy image interpretation. For pancreatic cysts, glucose, selected genomics (eg, KRAS/GNAS and targeted panels), and through-the-needle biopsy refine diagnosis. Finally, EUS-obtained tissue now seeds organoids, patient-derived xenografts, and organotypic slice cultures to test individualized therapies. Collectively, these innovations move EUS beyond "see and biopsy" toward detect, predict, and personalize.

> **中文摘要：**
> 内镜超声（EUS）已从单纯的诊断影像工具发展成为一种多功能平台，可在胃肠道和肝胆疾病中实现高精度的进入、取样和治疗。本综述总结了正在重塑诊断实践和治疗诊断一体化（theragnostics）的最新进展。在慢性胰腺炎中，当横断面影像结果不确定时，EUS仍是核心；促胰液素刺激的内镜胰腺功能测试可补充形态学评估，尽管两者结果不一致时会限制独立诊断的确定性。对于胰腺癌，促胰液素刺激的十二指肠胰液采集可实现“液体活检”分析——包括甲基化DNA标志物和细胞外囊泡microRNA——这些方法可增强糖链抗原19-9的诊断效能，并有望改进早期检测与囊性病变监测。在内镜肝病学领域，EUS引导的门静脉压力梯度测定和肝穿刺活检能够在同一操作中提供精准、安全的评估。辅助影像技术——增强EUS和弹性成像——改进了病灶表征与靶向取样。组织获取技术已转向采用端切式细针活检针，并通过扇扫/扭矩操作、湿吸取及宏观/实时视觉现场评估等方式优化，在减少穿刺次数的同时保持分子分析的充分性。人工智能正逐步应用于EUS工作流程之中——从胰腺病灶鉴别、分期，到标准化影像记录和报告的自动化处理——并正被探索用于针基共聚焦激光内显微图像的解读。在胰腺囊性病变中，葡萄糖测定、特定基因组学分析（如KRAS/GNAS及目标基因面板）以及针内穿刺活检进一步优化了诊断。最后，通过EUS获取的组织样本如今被用于构建类器官、患者源异种移植模型及器官切片培养，以测试个体化治疗。总体而言，这些创新推动EUS从“观察与活检”迈向“检测、预测与个体化”。

### 第二部分 AI 大师评价

该综述系统阐述了内镜超声在消化及肝胆疾病诊断中的最新拓展与前沿应用，突出了从结构影像到功能、分子和人工智能时代的演变。文章重心在于总结EUS在慢性胰腺炎、胰腺癌、内镜肝病学及囊性病变诊断中的创新方法与技术融合。综述显示EUS正由传统的“诊断影像与活检”工具演变为精确、个体化医疗的平台，其突出创新在于“液体活检”、AI辅助决策及组织工程应用。然而，实际推广仍需验证成本效益与跨机构可重复性。

---

## 7. 用于癌症诊疗一体化的刺激响应型超分子生物材料

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498647)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41498647
**DOI：** 10.1002/advs.202515860

### 第一部分 原文与翻译

**英文原标题：** Stimuli-Responsive Supramolecular Biomaterials for Cancer Theranostics.

> **英文摘要：**
> The ultimate goal of cancer theranostics is to deliver imaging agents and therapeutic cargo to tumor sites when and where they are required. "Smart" systems─including targeted and tailored releases with excellent spatial, temporal, and dosage control─should be developed. Supramolecular interactions with dynamic, reversible, and directional features enable the design of biomaterials with ordered architectures, tailored morphologies, multiple types of cargo, and controllable functions. Such supramolecular biomaterials are good candidates for oncology applications, as they optimize therapeutic efficacy while minimizing systemic adverse effects. This review summarizes recent advances in intelligent supramolecular biomaterials, with a specific focus on their spatiotemporal control in cancer theranostics. These biomaterials exploit endogenous and exogenous stimuli to trigger their morphological transformation. In particular, their construction approach and working mechanism, which are crucial in guiding tumor theranostics, are elaborated. Furthermore, the significant challenges in clinical translation and future perspectives for such biomaterials are discussed.

> **中文摘要：**
> 癌症诊疗一体化的最终目标是在所需的时间和部位，将影像剂和治疗载荷精准输送至肿瘤部位。应当开发包括靶向性和定制释放机制在内的“智能”系统，从而实现卓越的空间、时间及剂量控制。具有动态、可逆及方向性特征的超分子相互作用，使得能够设计出具有有序结构、可调形貌、可携带多种载荷且功能可控的生物材料。此类超分子生物材料是肿瘤学应用的良好候选者，因为它们能在优化治疗效果的同时最大限度地降低系统性不良反应。本综述总结了智能超分子生物材料的最新进展，特别关注其在癌症诊疗一体化中的时空控制特性。这些生物材料利用内源性和外源性刺激来触发其形态转变。文中详细阐述了其构建方法与工作机制，这对于指导肿瘤诊疗具有关键意义。此外，还讨论了此类生物材料在临床转化中的主要挑战及未来发展前景。

### 第二部分 AI 大师评价

本文综述了刺激响应型超分子生物材料在癌症诊疗一体化中的最新研究进展。作者重点阐述了这类材料如何通过动态可逆的超分子相互作用，实现空间与时间上的精确控制，并利用内外源刺激触发功能转变。该研究的创新点在于整合了智能设计理念与生物响应机制，为精准肿瘤诊疗提供了新思路。然而，文章也指出其在临床转化中仍面临诸多挑战，如生物安全性、可控性及复杂环境下的稳定性问题。整体而言，该综述为未来智能生物材料的开发方向提供了重要理论启示。

---

## 8. 单核多组学揭示鼻窦鳞状细胞癌中缺氧驱动的血管生成程序及其表观遗传调控。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498635)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41498635
**DOI：** 10.1002/advs.202510302

### 第一部分 原文与翻译

**英文原标题：** Single-Nucleus Multi-Omics Reveals Hypoxia-Driven Angiogenic Programs and Their Epigenetic Control in Sinonasal Squamous Cell Carcinoma.

> **英文摘要：**
> Sinonasal squamous cell carcinoma (SNSCC) is a rare malignancy with poorly understood molecular drivers. Consequently, its cellular composition and tumor microenvironment (TME) remain largely undefined. Here, we performed integrated bulk and single-nucleus multi-omic analyses to map the SNSCC ecosystem. Within the malignant compartment, we identified five distinct populations, with hypoxic (TC1) and proliferative (TC2) subtypes associated with adverse clinical outcomes. Functionally, TC1 cells orchestrate a hypoxia-driven angiogenic program via coordinated secretion of adrenomedullin (ADM), MIF, and VEGFA, promoting endothelial tip cell (EC1) differentiation. Integrative analysis revealed these transcriptional programs are underpinned by tumor-specific chromatin accessibility and DNA hypomethylation, particularly at AP-1-enriched regulatory elements. Mechanistically, in vitro studies confirmed that this response depends on cooperative AP-1 and HIF1A signaling. Furthermore, histological analysis of patient tissues demonstrated spatial co-localization of GLUT1-expressing TC1 cells with DLL4-positive EC1 cells. These findings elucidate the epigenetic landscape underlying tumor-stromal interactions and establish the ADM/VEGFA axis as a critical therapeutic target to disrupt epigenetically controlled angiogenesis in SNSCC.

> **中文摘要：**
> 鼻窦鳞状细胞癌（SNSCC）是一种罕见的恶性肿瘤，其分子驱动因素尚不明确。因此，其细胞组成及肿瘤微环境（TME）在很大程度上仍未被定义。在本研究中，我们进行了整合的总体和单核多组学分析，以描绘SNSCC的生态系统。在恶性细胞群中，我们鉴定出五种不同的群体，其中缺氧型（TC1）和增殖型（TC2）亚型与不良的临床结局相关。从功能上看，TC1细胞通过协调分泌肾上腺髓质素（ADM）、巨噬细胞迁移抑制因子（MIF）和血管内皮生长因子A（VEGFA），启动了一个缺氧驱动的血管生成程序，促进内皮尖端细胞（EC1）的分化。综合分析表明，这些转录程序由肿瘤特异性的染色质可及性和DNA低甲基化所支撑，尤其集中在富含AP-1的调控元件处。从机制上看，体外研究证实该反应依赖于AP-1与HIF1A信号的协同作用。此外，对患者组织的组织学分析显示，表达GLUT1的TC1细胞与表达DLL4的EC1细胞在空间上共定位。这些发现揭示了肿瘤—基质相互作用的表观遗传学景观，并确定ADM/VEGFA轴是破坏表观遗传控制的血管生成过程的关键治疗靶点，为SNSCC的治疗提供了新思路。

### 第二部分 AI 大师评价

本研究系统描绘了鼻窦鳞状细胞癌的细胞组成与表观遗传调控机制，结合单核多组学揭示了缺氧驱动的血管生成程序。通过多层组学整合与体外功能验证，研究阐明了AP-1与HIF1A协同调控肿瘤血管生成的机制，并确认ADM/VEGFA轴为潜在治疗靶点。其创新性在于揭示了SNSCC中肿瘤细胞与内皮细胞的空间互作及其表观遗传基础，但样本规模和体内验证仍有限，未来临床转化仍需进一步研究。

---

## 9. CsdA-LaeB 调控枢纽通过 Fumiquinazoline C 生物合成促进烟曲霉的毒力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498629)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41498629
**DOI：** 10.1002/advs.202519021

### 第一部分 原文与翻译

**英文原标题：** CsdA-LaeB Regulatory Hub Contributes to Aspergillus fumigatus Virulence via Fumiquinazoline C Biosynthesis.

> **英文摘要：**
> Fungal secondary metabolism plays a critical role in pathogen-host interactions, yet the regulatory networks linking metabolic reprogramming to virulence remain poorly understood. This study identifies a conserved regulatory hub in the human pathogen Aspergillus fumigatus, where the RNA-binding protein (RBP) CsdA interacts with the global regulator LaeB in the nucleus to regulate biosynthesis of the secondary metabolite fumiquinazoline C (FqC). Disruption of the CsdA-LaeB interaction hyperactivates FqC production, enhancing fungal colonization and lethality in murine invasive aspergillosis models. Integrative metabolomic and transcriptomic analyses reveal that CsdA and LaeB function as co-regulators of a broader secondary metabolic gene cluster network, with FqC emerging as an effector that mediates virulence in vivo. Genetic validation confirms that FqC is strictly required for the increased virulence phenotype of CsdA- or LaeB-deficient strains, while analyses of clinical isolates demonstrate a striking inverse correlation: reduced CsdA and LaeB expression coincides with elevated FqC production, showing consistency with the infection outcomes of the deletion mutants. This work identifies the RBP-based interaction that regulates fungal metabolic virulence, shedding new light on the post-transcriptional regulatory logic linking secondary metabolism to pathogenicity and offering alternative strategies for diagnostic development and therapeutic intervention in invasive fungal diseases.

> **中文摘要：**
> 真菌的次级代谢在病原体与宿主相互作用中发挥关键作用，但将代谢重编程与毒力联系起来的调控网络仍知之甚少。本研究在人体病原真菌烟曲霉中鉴定出一个保守的调控枢纽，其中 RNA 结合蛋白（RBP）CsdA 在细胞核内与全局调控因子 LaeB 相互作用，从而调节次级代谢产物 fumiquinazoline C（FqC）的生物合成。破坏 CsdA-LaeB 相互作用会导致 FqC 产生过度激活，在小鼠侵袭性曲霉病模型中增强真菌定植能力和致死性。整合代谢组学和转录组学分析表明，CsdA 和 LaeB 作为更广泛次级代谢基因簇网络的共调控因子协同作用，FqC 则作为体内介导毒力的效应分子出现。遗传学验证显示，FqC 对 CsdA 或 LaeB 缺失菌株所表现出的增强毒力表型是严格必需的；而临床分离株的分析则揭示出显著的反向相关性：CsdA 和 LaeB 表达降低与 FqC 产量升高相一致，这与缺失突变体的感染结局保持一致。本研究揭示了一种基于 RNA 结合蛋白的相互作用，在调控真菌代谢性毒力中发挥关键作用，为连接次级代谢与致病性的转录后调控逻辑提供了新的见解，并为侵袭性真菌病的诊断开发和治疗干预提供了替代策略。

### 第二部分 AI 大师评价

该研究聚焦于烟曲霉的代谢性毒力调控机制，鉴定了由 RNA 结合蛋白 CsdA 与全局调控因子 LaeB 组成的关键调控枢纽。研究通过代谢组学与转录组学整合分析揭示两者协同调控 Fumiquinazoline C 的生物合成，并证实该代谢产物在体内介导毒力的核心作用。工作创新地揭示了 RNA 水平的代谢毒力调控逻辑，拓展了对真菌致病性分子基础的理解。然而，机制的动态调控细节及在不同病理环境下的普适性仍需进一步研究。

---

## 10. TP53BP2 通过 G9a 与 DNMT1 协同调控 E2F1 促进胎盘自噬并加重子痫前期。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498597)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41498597
**DOI：** 10.1002/advs.202516408

### 第一部分 原文与翻译

**英文原标题：** TP53BP2 Promotes Placental Autophagy and Preeclampsia via G9a and DNMT1 Cooperatively Modulating E2F1.

> **英文摘要：**
> Preeclampsia (PE) is a pregnancy-related disorder characterized by impaired migration and invasion of trophoblast cells. Recent studies have highlighted the critical role of autophagy in the development of PE. However, the precise mechanisms underlying the upregulation of autophagy in PE remain unclear. This study demonstrated that the expression of the tumor suppressor p53-binding protein 2 (TP53BP2) is significantly upregulated in patients with PE. Silencing of TP53BP2 not only decreases autophagy but also attenuates PE progression in rat model. Moreover, TP53BP2 expression was positively correlated with blood pressure and body mass index (BMI) but negatively correlated with gestational age at delivery and neonatal birth weight. Our findings suggest that TP53BP2 enhances autophagy by promoting the release of Beclin-1 from the Bcl-2/Beclin-1 complex. Additionally, DNMT1 and G9a cooperatively downregulated TP53BP2 expression by reducing DNA methylation and H3K9me2 enrichment in the TP53BP2 promoter region. Importantly, the cooperation between DNMT1 and G9a suppressed E2F1 binding to the TP53BP2 promoter, leading to transcriptional repression of TP53BP2 in trophoblasts. In brief, our study indicates that TP53BP2 promotes autophagy in trophoblasts through DNA methylation and H3K9me2-mediated transcriptional regulation. These findings suggest that targeting TP53BP2 may be a potential therapeutic strategy for PE.

> **中文摘要：**
> 子痫前期（PE）是一种妊娠相关疾病，其特征为滋养层细胞迁移和侵袭能力受损。近期研究强调了自噬在 PE 发生发展中的关键作用。然而，PE 中自噬上调的精确机制仍不清楚。本研究表明，肿瘤抑制蛋白 p53 结合蛋白 2（TP53BP2）的表达在 PE 患者中显著上调。沉默 TP53BP2 不仅降低自噬水平，还在大鼠模型中减轻了 PE 的进展。此外，TP53BP2 的表达与血压和体重指数（BMI）呈正相关，而与分娩孕周和新生儿出生体质量呈负相关。研究结果提示，TP53BP2 可通过促进 Beclin-1 从 Bcl-2/Beclin-1 复合物中释放来增强自噬活性。此外，DNMT1 与 G9a 通过降低 TP53BP2 启动子区域 DNA 甲基化和 H3K9me2 富集水平协同下调 TP53BP2 的表达。重要的是，DNMT1 与 G9a 的协同作用抑制了转录因子 E2F1 与 TP53BP2 启动子的结合，从而介导滋养层细胞中 TP53BP2 的转录抑制。总之，本研究表明 TP53BP2 可通过 DNA 甲基化与 H3K9me2 介导的转录调控促进滋养层细胞自噬。这些结果提示，靶向 TP53BP2 可能成为治疗子痫前期的潜在策略。

### 第二部分 AI 大师评价

本文聚焦于 TP53BP2 在子痫前期发病机制中的表观遗传调控作用。作者通过患者样本与动物模型揭示 TP53BP2 上调可促进滋养层自噬并加重疾病进展；同时指出 DNMT1 与 G9a 协同通过抑制 E2F1 结合下调 TP53BP2。研究创新性地连接了自噬与表观修饰调控网络，揭示了 TP53BP2 在胎盘功能障碍中的新作用。但其机制仍需更多临床样本与功能验证研究支持。

---

## 11. 数据驱动反馈识别优化的聚焦超声暴露方案以改进脑部纳米诊疗靶向效果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498583)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41498583
**DOI：** 10.1002/advs.202517834

### 第一部分 原文与翻译

**英文原标题：** Data-Driven Feedback Identifies Focused Ultrasound Exposure Regimens for Improved Nanotheranostic Targeting of the Brain.

> **英文摘要：**
> The blood-brain barrier (BBB) renders the delivery of nanomedicine in the brain ineffective and the detection of circulating disease-related DNA from the brain unreliable. Here, we demonstrate that microbubble-enhanced focused ultrasound (MB-FUS) mediated BBB opening, supported by large-data models predict sonication regimens for safe and effective BBB opening. Importantly, a closed-loop MB-FUS controller augmented by machine learning (ML-CL) expands the treatment window, as compared to conventional controllers, by persistently and proactively maximizing the BBB permeability while preventing tissue damage. By successfully scaling up from mice to rats and from healthy to diseased brains (glioma), ML-CL rendered the BBB permeable to large nanoparticles and markedly improved the release and detection of reporter gene DNA from tumors in blood. Together, our findings reveal the potential of data-driven feedback to support the development of next-generation AI-powered ultrasound systems for safe, robust, and efficient nanotheranostic targeting and treatment of brain diseases.

> **中文摘要：**
> 血脑屏障（BBB）使得纳米药物在脑内的递送效率低下，同时降低了从脑部检测循环中疾病相关DNA的可靠性。本研究表明，微泡增强聚焦超声（MB-FUS）介导的BBB开放可借助大数据模型预测声照射方案，从而实现安全且有效的屏障开启。重要的是，与传统控制器相比，经机器学习增强的闭环MB-FUS控制器（ML-CL）能够持续且主动地最大化BBB通透性，同时避免组织损伤，从而显著拓展治疗窗口。通过从小鼠成功扩展到大鼠、并从健康脑转向病变脑（胶质瘤）的实验，ML-CL 使得BBB对大尺寸纳米颗粒具有通透性，并显著改善了血液中肿瘤来源报告基因DNA的释放与检测。综上所述，本研究揭示了数据驱动反馈在支持下一代人工智能驱动超声系统开发中的潜力，为脑部疾病的安全、稳健且高效的纳米诊疗靶向和治疗提供了新方向。

### 第二部分 AI 大师评价

该研究旨在通过引入机器学习增强的闭环控制系统，优化微泡聚焦超声介导的血脑屏障开放策略。研究团队利用大数据模型预测和调整声功率参数，实现了在保证安全性的前提下最大化BBB的通透性。结果表明，该方法不仅可扩展至不同动物模型及病理状态，还显著提升了脑部纳米药物的进入效率及血液中肿瘤DNA的检测灵敏度。创新性在于将AI反馈控制融入超声治疗系统，为智能化脑部精准治疗开辟了新途径，但后续在临床适用性和跨物种模型的稳健性验证仍需进一步研究。

---

## 12. 探究Y染色体：Y染色体缺失如何促进老年男性心血管疾病的发生？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498477)
**期刊：** Journal of the American College of Cardiology
**PMID：** 41498477
**DOI：** 10.1016/j.jacc.2025.11.040

### 第一部分 原文与翻译

**英文原标题：** Wondering Y: How Might Loss of the Y Chromosome Promote Cardiovascular Disease in Aging Men?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究标题探讨了Y染色体缺失与老年男性心血管疾病之间的潜在因果关联，提示作者可能旨在阐明遗传与性别特异性因素在心血管老化过程中的作用。虽然目前尚无摘要，此主题蕴含较高的研究创新性，可能涉及分子遗传、炎症反应与细胞功能衰退的交集。未来若能结合多组学及纵向人群数据，将有助于揭示Y染色体丢失对男性心血管健康的生物学机制与临床意义。

---

## 13. 男性Y染色体缺失与老年男性主要心血管事件的前瞻性研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498476)
**期刊：** Journal of the American College of Cardiology
**PMID：** 41498476
**DOI：** 10.1016/j.jacc.2025.10.069

### 第一部分 原文与翻译

**英文原标题：** Loss of Y Chromosome and Major Cardiovascular Events in a Prospective Study of Older Men.

> **英文摘要：**
> BACKGROUND: Loss of the Y chromosome (LOY) from a percentage of circulating leukocytes is common in older men and is associated with cardiovascular risk. However, most studies have involved men with preexisting disease, not healthy men followed prospectively.
> 
> OBJECTIVES: This study sought to investigate the association between LOY and risk of incident major adverse cardiovascular events (MACEs), including myocardial infarction (MI) and ischemic stroke.
> 
> METHODS: This study included 5,131 men aged ≥ 65 years from the ASPREE (ASPirin in Reducing Events in the Elderly) trial with no prior cardiovascular disease at baseline. LOY percentage was measured in peripheral blood using microarrays and the log-R-ratio method. MACEs, including MI and ischemic stroke, were collected during the trial and subsequent observational follow-up. Cox regression assessed associations of LOY as a continuous (per SD) and categorical (decile-based) variable. Deciles 1 through 6 (reference) represented no LOY, deciles 7 through 9 moderate, and decile 10 substantial.
> 
> RESULTS: Over a median of 8.4 years of follow-up, 9.8% men (n = 505) experienced MACEs, with 5% (n = 256) MI and 4% (n = 207) ischemic stroke. In the fully adjusted model, each SD increase in LOY was associated with 14% higher MI risk (HR per SD: 1.14; 95% CI: 1.02-1.28). Men with substantial LOY (decile 10) had 68% higher MI risk vs men without LOY (HR: 1.68; 95% CI: 1.16-2.54). No associations were observed for ischemic stroke. Results were robust to sensitivity analyses. In 191,340 men aged 40 to 70 years from the UK Biobank, LOY was also associated with MI (HR per SD: 1.03; 95% CI: 1.01-1.06).
> 
> CONCLUSIONS: LOY is associated with increased MI risk, but not stroke, in older men.

> **中文摘要：**
> 背景：在老年男性中，部分循环白细胞中Y染色体的丢失（LOY）是一种常见现象，并与心血管风险相关。然而，大多数研究涉及已有疾病的男性，而非对健康男性的前瞻性随访研究。
> 
> 目的：本研究旨在探讨LOY与主要不良心血管事件（MACE）的发生风险之间的关系，包括心肌梗死（MI）和缺血性卒中。
> 
> 方法：本研究纳入了ASPREE（阿司匹林在老年人事件减少中的作用）试验中5131名年龄≥65岁的男性，他们在基线时均无心血管疾病。通过微阵列和对数R比值法测量外周血中的LOY百分比。在试验期及后续观察性随访期间，收集了包括MI和缺血性卒中的MACE事件。采用Cox回归分析LOY作为连续（每标准差）和分类（按十分位）变量与事件风险的关联。第1至6十分位（参考组）代表无LOY，第7至9十分位为中等程度，第10十分位为显著LOY。
> 
> 结果：在中位8.4年的随访期间，9.8%的男性（n=505）发生MACE，其中5%（n=256）为MI，4%（n=207）为缺血性卒中。在完全调整模型中，每增加1个LOY标准差与MI风险增加14%相关（每标准差HR: 1.14；95% CI: 1.02–1.28）。具有显著LOY（第10十分位）的男性与无LOY者相比，MI风险增加68%（HR: 1.68；95% CI: 1.16–2.54）。未观察到LOY与缺血性卒中之间的关联。结果在敏感性分析中保持稳健。在来自英国生物样本库的191,340名年龄40–70岁的男性人群中，LOY亦与MI风险相关（每标准差HR: 1.03；95% CI: 1.01–1.06）。
> 
> 结论：LOY在老年男性中与心肌梗死风险增加相关，但与卒中无关。

### 第二部分 AI 大师评价

该研究通过在无既往心血管病的老年男性中前瞻性分析，揭示了外周血Y染色体缺失（LOY）与心肌梗死发生风险之间的独立关联。研究利用ASPREE试验和英国生物样本库两大人群数据，采用多维统计模型，结果具有较高的稳健性。发现LOY显著升高心肌梗死风险，而与缺血性卒中无关。该工作为男性特异性遗传改变与心血管疾病风险之间的联系提供了新的流行病学证据，但其机制仍需进一步研究。

---

## 14. 一种染色体易位在髓系白血病中作为新型癌基因的鉴定

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498402)
**期刊：** eLife
**PMID：** 41498402
**DOI：** 10.7554/eLife.93645

### 第一部分 原文与翻译

**英文原标题：** Identification of a  translocation as a novel oncogene in myeloid leukemia.

> **英文摘要：**
> Myeloid leukemias, diseases marked by aggressiveness and poor outcomes, are frequently triggered by oncogenic translocations. In the case of chronic myelogenous leukemia (CML), the BCR-ABL fusion initiates chronic phase disease with second hits allowing progression to blast crisis. Although Gleevec has been transformative for CML, blast crisis CML remains relatively drug resistant. Here, we show that , a translocation with an unknown role in cancer, can serve as a second hit in driving bcCML. Compared to BCR-ABL, BCR-ABL/MSI2-HOXA9 led to a more aggressive disease in vivo with decreased latency, increased lethality, and a differentiation blockade that is a hallmark of blast crisis. Domain mapping revealed that the  RNA binding domain RRM1 had a preferential impact on growth and lethality of bcCML relative to RRM2 or the HOXA9 domain. Mechanistically, MSI2-HOXA9 triggered global downstream changes with a preferential upregulation of mitochondrial components. Consistent with this, BCR-ABL/MSI2-HOXA9 cells exhibited a significant increase in mitochondrial respiration. These data suggest that MSI2-HOXA9 acts, at least in part, by increasing expression of the mitochondrial polymerase POLRMT and augmenting mitochondrial function and basal respiration in blast crisis. Collectively, our findings demonstrate for the first time that translocations involving the stem and developmental signal MSI2 can be oncogenic and suggest that MSI, which we found to be a frequent partner for an array of translocations, could also be a driver mutation across solid cancers.

> **中文摘要：**
> 髓系白血病是一组具有高度侵袭性和预后不良特征的疾病，常由致癌性染色体易位引发。在慢性髓性白血病（CML）中，BCR-ABL融合基因启动慢性期疾病，而“第二次打击”事件使其进展为爆发危象期。尽管格列卫（Gleevec）极大改变了CML的治疗格局，但爆发危象期CML仍显示出较强的耐药性。在本研究中，我们发现一种此前在癌症中作用未知的染色体易位可作为促进爆发危象CML（bcCML）进展的“第二次打击”。与单纯的BCR-ABL相比，BCR-ABL/MSI2-HOXA9融合在体内引发了更具侵袭性的疾病，表现为潜伏期缩短、致死性增强以及分化受阻——这一特征是爆发危象的标志。结构域映射分析显示，RNA结合结构域RRM1相比RRM2或HOXA9结构域，对bcCML的生长和致死性具有更为显著的影响。从机制上看，MSI2-HOXA9引发了下游的全局性变化，尤其是线粒体组分的上调。与此一致，BCR-ABL/MSI2-HOXA9细胞的线粒体呼吸显著增强。这些数据提示，MSI2-HOXA9至少部分通过上调线粒体聚合酶POLRMT的表达，从而增强线粒体功能和基础呼吸以促进爆发危象期的发生。总体而言，我们的研究首次证明涉及MSI2这一干细胞与发育信号分子的易位具有致癌潜能，并提示MSI2可作为多种易位事件的常见伙伴，甚至可能是多种实体瘤中的驱动突变。

### 第二部分 AI 大师评价

该研究旨在揭示一种新发现的染色体易位在髓系白血病中的致癌作用，特别是在CML爆发危象期的进展机制。作者通过建立BCR-ABL/MSI2-HOXA9模型，发现该融合显著促进疾病侵袭性并导致分化阻滞。结构域分析明确了RRM1结构域的关键作用，代谢研究进一步指出MSI2-HOXA9可通过上调线粒体功能驱动病程进展。研究首次证明了MSI2相关易位的致癌潜能，拓展了对白血病分子机制的认识，但仍需更多临床验证和机制完善以评估其治疗靶点潜力。

---

## 15. 复制应激诱导的ELF3上调促进BRCA1缺陷型乳腺腔面祖细胞的肿瘤发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498327)
**期刊：** eLife
**PMID：** 41498327
**DOI：** 10.7554/eLife.89573

### 第一部分 原文与翻译

**英文原标题：** Replication stress-inducing ELF3 upregulation promotes BRCA1-deficient breast tumorigenesis in luminal progenitors.

> **英文摘要：**
> BRCA1 is a critical tumor suppressor, mutations in which greatly increase risks for many tumors in carriers, most notably breast cancer. Luminal progenitor cells (LPs) are the currently recognized cells of origin of BRCA1-deficient breast cancers. However, the reason why LPs are prone to transform with BRCA1 deficiency has not been elucidated. Here, using single-cell sequencing of human  mutant breast cancers and RNA sequencing (RNA-seq) of -deficient normal mammary cells, we reveal that replication stress is a feature of LPs and a driving factor during BRCA1-associated tumorigenesis. Mechanistically, replication stress and BRCA1 deficiency lead to significant upregulation of ELF3 expression. ELF3 can help suppress excessive genomic instability and promote LP transformation with BRCA1 deficiency. Moreover, ELF3 emerged as a core transcription factor regulating LP genes, leading to LP expansion. Our findings suggest that replication stress is a driving factor during BRCA1-associated tumorigenesis in luminal progenitor cells and elucidates the key role of ELF3 during this process.

> **中文摘要：**
> BRCA1 是一种关键的肿瘤抑制因子，其突变会显著增加携带者患多种肿瘤的风险，尤其是乳腺癌。腔面祖细胞（LPs）目前被认为是 BRCA1 缺陷型乳腺癌的起源细胞。然而，为什么在 BRCA1 缺陷条件下 LPs 更易发生转化的原因尚未阐明。在本研究中，我们利用人 BRCA1 突变乳腺癌的单细胞测序以及 BRCA1 缺陷正常乳腺细胞的 RNA 测序（RNA-seq），揭示了复制应激是 LPs 的特征，并且是 BRCA1 相关肿瘤发生过程中的驱动因素。从机制上看，复制应激与 BRCA1 缺陷会导致 ELF3 表达显著上调。ELF3 能够帮助抑制过度的基因组不稳定性，并促进 BRCA1 缺陷条件下的 LP 转化。此外，ELF3 被发现是调控 LP 基因的核心转录因子，促进 LP 扩增。我们的研究结果表明，复制应激是 BRCA1 相关乳腺腔面祖细胞肿瘤发生的驱动力，并阐明了 ELF3 在此过程中的关键作用。

### 第二部分 AI 大师评价

本文聚焦于 BRCA1 缺陷乳腺癌的细胞起源机制，通过单细胞测序和 RNA-seq 揭示复制应激是腔面祖细胞中肿瘤发生的重要驱动力量。研究发现 BRCA1 缺陷与复制应激共同导致 ELF3 显著上调，而 ELF3 既可抑制过度基因组不稳定，又促进细胞转化及扩增。此研究在机制层面清晰地界定了 ELF3 的双重作用，深化了对 BRCA1 相关乳腺癌发生机制的理解。其创新性在于揭示复制应激—ELF3 轴的关键调控网络，但仍需要进一步在体内验证其因果关系与治疗潜力。

---

## 16. CXCR6 T细胞驱动免疫检查点抑制剂相关心肌炎

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498147)
**期刊：** Circulation
**PMID：** 41498147
**DOI：** 10.1161/CIRCULATIONAHA.125.076976

### 第一部分 原文与翻译

**英文原标题：** CXCR6 T Cells Drive Immune Checkpoint Inhibitor Myocarditis.

> **英文摘要：**
> BACKGROUND: Myocarditis is a severe complication of immune checkpoint inhibitors (ICIs). The major risk factor for ICI myocarditis is the use of combination ICI treatment, especially when relatlimab, a novel anti-LAG-3 (lymphocyte-activation gene 3) antibody, is combined with anti-PD-1 (programmed cell death protein 1) therapy. Although pathogenic T cells are necessary for ICI myocarditis, the specific signaling and T-cell populations that drive cardiac infiltration have not been fully elucidated, especially in setting of anti-LAG-3/PD-1 treatment.
> 
> METHODS: We used VigiBase, an international pharmacovigilance database, to assess the risk of myocarditis with anti-LAG-3 compared with other ICI treatment regimens. We identified a mouse model of LAG-3/PD-1-associated ICI myocarditis through genetic deletion of immune checkpoints LAG-3 and PD-1 ( mice) and performed rigorous cardiac phenotyping using histology, flow cytometry, electrocardiography, single-cell RNA sequencing, and antibody-induced cellular depletion.
> 
> RESULTS: We found an increased risk of myocarditis with anti-LAG-3 combination treatment clinically, confirming early clinical trial data.  mice were found to develop severe cardiac inflammation by histology with increased cardiac macrophages and clonal T cells, which was associated with the development of spontaneous arrhythmias leading to premature death by 6 to 8 weeks. We identified CXCR6 (C-X-C motif chemokine receptor 6) as a key marker of activated cardiac T cells in this model, along with analogous signals in other preclinical models and patient data. CXCR6 marked a heterogenous group of cardiac T cells, including distinct clusters of , , , and actively dividing T cells. CXCL16 (C-X-C motif chemokine ligand 16), the sole known ligand for CXCR6, was similarly upregulated in the cardiac macrophage population. Treatment with anti-CXCR6 antibody prevented premature lethality, attenuated arrhythmias, and reduced the histological severity of myocarditis, demonstrating that CXCR6 T cells are necessary for disease pathogenesis.
> 
> CONCLUSIONS: Our findings suggest that ICI myocarditis is driven by an expansion of CXCR6 T cells and identifies CXCR6 as a putative therapeutic target for this highly morbid condition.

> **中文摘要：**
> 背景：心肌炎是免疫检查点抑制剂（ICIs）的一种严重并发症。ICI相关心肌炎的主要风险因素是联合ICI治疗的使用，尤其是在新型抗LAG-3（淋巴细胞活化基因3）抗体relatlimab与抗PD-1（程序性细胞死亡蛋白1）治疗联合时。尽管致病性T细胞在ICI心肌炎中必不可少，但驱动心脏浸润的特定信号途径和T细胞群体尚未完全阐明，尤其是在抗LAG-3/PD-1治疗条件下。
> 
> 方法：我们使用国际药物警戒数据库VigiBase，评估了抗LAG-3与其他ICI治疗方案相比的心肌炎风险。通过免疫检查点LAG-3和PD-1的基因缺失（小鼠）建立了LAG-3/PD-1相关ICI心肌炎的小鼠模型，并利用组织学、流式细胞术、心电图、单细胞RNA测序以及抗体介导的细胞消除技术进行了严格的心脏表型分析。
> 
> 结果：我们发现临床上抗LAG-3联合治疗的心肌炎风险增加，与早期临床试验数据一致。组织学结果显示，双基因缺失小鼠出现严重的心脏炎症，伴随心脏巨噬细胞及克隆性T细胞增多，并发展为自发性心律失常，导致在6至8周内的早死。我们在该模型中鉴定出CXCR6（C-X-C基序趋化因子受体6）是活化心脏T细胞的关键标志物，并在其他临床前模型及患者数据中观察到类似信号。CXCR6标识了一组异质性的心脏T细胞群体，包括不同的T细胞亚群及活跃分裂的T细胞。其唯一已知配体CXCL16（C-X-C基序趋化因子配体16）也在心脏巨噬细胞群体中上调。使用抗CXCR6抗体治疗可防止早死，减轻心律失常，并降低心肌炎的组织学严重程度，表明CXCR6 T细胞是疾病发病机制中的关键因素。
> 
> 结论：我们的研究结果表明，ICI相关心肌炎由CXCR6 T细胞的扩增驱动，并提示CXCR6可能成为这种高致病状态的潜在治疗靶点。

### 第二部分 AI 大师评价

该研究聚焦于免疫检查点抑制剂引发的心肌炎机制，揭示CXCR6 T细胞在其中的关键作用。研究采用药物警戒数据库分析与LAG-3/PD-1双缺失小鼠模型，结合单细胞转录组和功能学验证，系统阐释CXCR6信号通路在心脏免疫炎症中的致病性。结果证明阻断CXCR6可有效减轻病情，突出其作为新型治疗靶点的潜力。其创新之处在于跨临床与实验模型验证关键免疫细胞亚群，但模型可推广性及临床转化仍需进一步研究。

---

## 17. 高通量药物筛选揭示卵巢癌肉瘤类器官模型中EGFR/MAPK通路靶向的敏感性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495830)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41495830
**DOI：** 10.1186/s13046-025-03629-8

### 第一部分 原文与翻译

**英文原标题：** High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma.

> **英文摘要：**
> BACKGROUND: Ovarian carcinosarcoma (OCS) is a rare and aggressive tumour type with limited treatment options. Standard therapy includes platinum agents, but responses are poor. OCS highly express mesenchymal markers, such as N-MYC and HMGA2. The microtubule-targeting drug eribulin can reduce expression of N-MYC and HMGA2 in OCS PDX models and functionally reverse EMT in OCS cell lines.
> 
> METHODS: In this study, we carried out drug screens in the presence of cisplatin or eribulin to identify synergistic combinations. We validated top combinations in our unique OCS cell line, organoid and PDX models.
> 
> RESULTS: The most effective combination treatments in OCS organoid models involved eribulin, whereas cisplatin-based combination therapies were more effective in high-grade serous ovarian cancer (HGSOC) models. Eribulin combined with either an EGFR inhibitor (erlotinib) or a MEK inhibitor (mirdametinib/PD0325901) were the most effective combinations in OCS models, with a synergistic effect being observed in two (out of four) models for each combination. Mechanistically, OCS models appeared to be particularly reliant on EGFR and MAPK signalling in vitro, especially in tumours with TP53 mutation. In vivo, only modest improvements in survival were observed for eribulin plus erlotinib, however, two of the three OCS PDX models tested were found to have drug resistance mechanisms, such as high ABCB1 expression (encoding the multi-drug resistance protein which causes drug efflux) or a KRAS constitutive activation mutation (a known resistance mechanism to EGFR inhibitors). KRAS mutant OCS cell lines and organoids were sensitive to dual targeting of the EGFR/MAPK pathway, with statistically greater synergy observed when eribulin was added as a third drug.
> 
> CONCLUSIONS: OCS is the most aggressive, drug-resistant gynaecological malignancy and eribulin-based combination therapies, particularly triple combination therapies, have the potential to improve patient outcomes.

> **中文摘要：**
> 背景：卵巢癌肉瘤（OCS）是一种罕见且侵袭性极强的肿瘤类型，治疗选择有限。标准治疗包括铂类药物，但疗效欠佳。OCS高度表达间质标志物，如N-MYC和HMGA2。微管靶向药物厄吡林可在OCS患者来源异种移植（PDX）模型中降低N-MYC和HMGA2的表达，并在OCS细胞系中功能性逆转上皮-间质转化（EMT）。
> 
> 方法：在本研究中，我们在顺铂或厄吡林存在的条件下进行药物筛选，以鉴定具有协同效应的药物组合。我们在独特的OCS细胞系、类器官及PDX模型中验证了最优组合。
> 
> 结果：在OCS类器官模型中，最有效的联合治疗方案均涉及厄吡林；而顺铂为基础的联合疗法在高级别浆液性卵巢癌（HGSOC）模型中更为有效。厄吡林与EGFR抑制剂（厄洛替尼）或MEK抑制剂（mirdametinib/PD0325901）联合使用在OCS模型中表现出最强效应，每种组合在四个模型中的两个显示出协同作用。从机制上看，OCS模型在体外表现出对EGFR和MAPK信号通路的高度依赖，尤其是在TP53突变的肿瘤中。体内研究显示，厄吡林联合厄洛替尼仅带来适度的生存期改善。然而，在三种接受测试的OCS PDX模型中，有两种发现存在耐药机制，如ABCB1高表达（编码导致药物外排的多药耐药蛋白）或KRAS组成型激活突变（已知的EGFR抑制剂耐药机制）。KRAS突变的OCS细胞系和类器官对EGFR/MAPK通路的双重靶向治疗表现出敏感性，而当厄吡林作为第三种药物加入时，观察到统计学上显著增强的协同效应。
> 
> 结论：OCS是最具侵袭性且耐药性最强的妇科恶性肿瘤之一，以厄吡林为基础的联合治疗，特别是三药组合疗法，有望改善患者的临床预后。

### 第二部分 AI 大师评价

本研究聚焦于卵巢癌肉瘤这一罕见且耐药性强的肿瘤，利用高通量药物筛选探索潜在的联合疗法。研究结合细胞系、类器官及PDX模型，发现EGFR/MAPK通路在OCS中发挥关键作用，厄吡林与EGFR或MEK抑制剂联用在部分模型中产生显著协同效应。值得注意的是，KRAS突变与ABCB1高表达被确定为耐药机制揭示的关键因素。研究创新性地展示了EGFR/MAPK联合靶向策略在OCS中的潜力，但同时指出其体内疗效有限和耐药问题亟待进一步研究。

---

## 18. 通过循环无细胞染色体外环状DNA片段大小选择检测原发性癌症类型

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495807)
**期刊：** Genome medicine
**PMID：** 41495807
**DOI：** 10.1186/s13073-025-01595-6

### 第一部分 原文与翻译

**英文原标题：** Detection of primary cancer types via fragment size selection in circulating cell-free extrachromosomal circular DNA.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于利用循环无细胞染色体外环状DNA（eccDNA）的片段大小选择方法来识别原发性癌症类型，体现出无创肿瘤分型检测领域的创新思路。通过分析eccDNA片段长度分布特征，研究者可能试图揭示不同癌种间的特异性片段模式，以实现精准分类。此方向有望补充传统cfDNA测序或突变分析的不足，增强液体活检的诊断效能。但若无大样本验证，其泛化能力及临床可行性仍待进一步评估。

---

## 19. 多发性骨髓瘤风险与DNA损伤反应基因相关联

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495781)
**期刊：** Journal of hematology & oncology
**PMID：** 41495781
**DOI：** 10.1186/s13045-025-01776-1

### 第一部分 原文与翻译

**英文原标题：** Multiple myeloma risk linked to DNA damage response genes.

> **英文摘要：**
> BACKGROUND: DNA damage response genes (DDRG), implicated in several cancers as both predisposing risk factors as well as biomarkers for aggressiveness, have not been fully explored in multiple myeloma (MM).
> 
> METHODS: Herein, we analyzed disease associations of pathogenic variations in nine putative candidate genes using 3 446 MM cases and 323 233 cancer-free controls.
> 
> RESULTS: Increased MM risk was found to be associated with inherited rare pathogenic mutations in TP53, ATM, CHEK2, KDM1A, and ARID1A, with an enrichment of these variants among individuals with early onset or family history of MM. Individuals with TP53 or ATM germline mutations are also likely to have worse overall survival.
> 
> CONCLUSIONS: Our results suggest expansion of the phenotypic spectrum of some of these DDRG to include MM. The identification of these germline predisposition genes opens the avenue for targeted screening of higher risk individuals especially those with young-onset or a family history of plasma cell gammopathies.

> **中文摘要：**
> 背景：DNA损伤反应基因（DNA damage response genes，DDRG）在多种癌症中已被证明既是易感风险因素，又是肿瘤侵袭性的生物标志物，但其在多发性骨髓瘤（multiple myeloma，MM）中的作用尚未得到充分研究。
> 
> 方法：本研究分析了9个推测候选基因的致病变异与疾病的关联性，研究样本包括3,446例MM患者和323,233名无癌对照者。
> 
> 结果：发现TP53、ATM、CHEK2、KDM1A和ARID1A基因中的遗传性罕见致病突变与MM风险增加相关，这些变异在早发或具有家族史的MM个体中更为富集。携带TP53或ATM生殖系突变的个体总体生存期可能较差。
> 
> 结论：我们的结果提示部分DDRG的表型谱可扩展至包括MM。这些生殖系易感基因的鉴定为针对高风险人群，特别是年轻发病或具有浆细胞病家族史人群的靶向筛查提供了新的途径。

### 第二部分 AI 大师评价

该研究旨在探索DNA损伤反应基因与多发性骨髓瘤易感风险之间的关联。通过对3446例患者及32万余对照样本的基因变异分析，研究发现TP53、ATM、CHEK2、KDM1A和ARID1A的罕见遗传突变与疾病风险显著相关，尤其在早发及家族史个体中富集。结果表明这些基因的生殖系突变不仅影响发病风险，还与整体生存相关。该研究扩展了DDRG的功能谱，为高危人群的精准筛查提供了新方向，但仍需在独立队列中进一步验证。

---

## 20. 撤稿说明：环状RNA circDCUN1D4 通过靶向 miR-590-5p/TIMP3 轴抑制肝细胞癌的发展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495780)
**期刊：** Molecular cancer
**PMID：** 41495780
**DOI：** 10.1186/s12943-025-02550-0

### 第一部分 原文与翻译

**英文原标题：** Retraction Note: Circular RNA circDCUN1D4 suppresses hepatocellular carcinoma development via targeting the miR-590-5p/ TIMP3 axis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文为撤稿声明，涉及原研究中一项关于环状RNA circDCUN1D4 在肝细胞癌中通过 miR-590-5p/TIMP3 信号轴发挥抑制作用的工作。撤稿说明意味着原报告的研究结果可能存在数据可靠性或方法学方面的问题。虽然此主题揭示了非编码RNA调控肝癌发生发展的潜在机制，但撤稿提示需要进一步验证其科学依据和实验可重复性。

---

## 21. Psammaplysene D 通过靶向 FGFR4/CYP26A1-视黄酸轴驱动铁死亡，从而克服肝癌中对索拉非尼的耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495759)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41495759
**DOI：** 10.1186/s13046-025-03622-1

### 第一部分 原文与翻译

**英文原标题：** Psammaplysene D overcomes sorafenib resistance in liver cancer by targeting FGFR4/CYP26A1-retinoic acid axis to drive ferroptosis.

> **英文摘要：**
> BACKGROUND: Overcoming sorafenib resistance remains a major challenge in liver cancer treatment. This study evaluates the novel compound Psammaplysene D, alone or combined with sorafenib, against liver cancer, focusing on overcoming resistance.
> 
> METHODS: The efficacy of Psammaplysene D, alone or with sorafenib, was assessed using liver cancer cell lines and xenograft mouse models, including sorafenib-resistant variants. The direct binding interaction between Psammaplysene D and FGFR4 was confirmed through molecular docking and Cellular Thermal Shift Assay (CETSA). Transcriptomic profiling (RNA-seq) identified key differentially expressed genes. Ferroptosis induction was evaluated using key markers, and functional roles were validated using genetic and pharmacological approaches.
> 
> RESULTS: Psammaplysene D inhibited liver cancer growth in vitro and in vivo, alone or synergistically with sorafenib, and overcame sorafenib resistance in both models. Mechanistic investigations revealed that Psammaplysene D directly targets FGFR4, inducing ferroptosis. In sorafenib-resistant cells, Psammaplysene D downregulates CYP26A1 expression, elevating retinoic acid (RA) levels. FGFR4 inhibition triggered ferroptosis and reduced CYP26A1 expression, while accumulated RA drove ferroptosis in resistant cells.
> 
> CONCLUSIONS: Overall, Psammaplysene D is a potent therapeutic agent for liver cancer, effective alone or combined with sorafenib, and overcomes resistance through direct targeting of FGFR4, initiating a cascade of CYP26A1 downregulation, RA accumulation, and ferroptosis induction-defining a novel FGFR4/CYP26A1/RA axis regulating ferroptosis in resistant liver cancer.

> **中文摘要：**
> 背景：克服索拉非尼耐药性仍然是肝癌治疗中的一项重大挑战。本研究评估了新型化合物 Psammaplysene D 单独使用或与索拉非尼联合应用在肝癌中的作用，重点探讨其克服耐药性的潜力。
> 
> 方法：采用肝癌细胞系和异种移植小鼠模型（包括索拉非尼耐药变体）评估 Psammaplysene D 单独或与索拉非尼联用的抗肝癌效果。通过分子对接和细胞热转变实验（CETSA）验证了 Psammaplysene D 与 FGFR4 的直接结合。通过转录组测序（RNA-seq）鉴定关键差异表达基因。利用关键标志物评估铁死亡的诱导情况，并通过基因学和药理学手段验证其功能作用。
> 
> 结果：Psammaplysene D 在体内外均能抑制肝癌生长，无论单独使用还是与索拉非尼联用，均表现出协同效应，并在两种模型中逆转索拉非尼耐药性。机制研究表明，Psammaplysene D 可直接靶向 FGFR4，诱导铁死亡。在索拉非尼耐药的细胞中，Psammaplysene D 下调 CYP26A1 表达，导致视黄酸（RA）水平升高。FGFR4 抑制可触发铁死亡并降低 CYP26A1 表达，而 RA 的积累进一步在耐药细胞中促进铁死亡。
> 
> 结论：总体而言，Psammaplysene D 是一种具有强效的肝癌治疗候选药物，无论单独使用还是与索拉非尼联合，均能通过直接靶向 FGFR4 克服耐药性，引发 CYP26A1 下调、RA 积累及铁死亡诱导的级联反应，从而定义了一个调控耐药肝癌铁死亡的新型 FGFR4/CYP26A1/RA 轴。

### 第二部分 AI 大师评价

本研究围绕肝癌索拉非尼耐药性难题，系统探究了海洋天然产物 Psammaplysene D 的抗耐药机制。研究团队结合分子对接、CETSA 验证、转录组分析及功能实验，揭示 Psammaplysene D 可通过抑制 FGFR4、下调 CYP26A1 并积累视黄酸，从而诱导铁死亡并逆转耐药性。该工作提出了新的 FGFR4/CYP26A1/RA 调控铁死亡信号轴，为耐药肝癌治疗提供了新思路。虽机制研究详实，但后续仍需临床前安全性及药代动力学验证以支持其药物转化潜力。

---

## 22. CAR 调适的 PIK3CD 碱基编辑增强了 T 细胞的抗肿瘤效能。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495526)
**期刊：** Nature cancer
**PMID：** 41495526
**DOI：** 10.1038/s43018-025-01099-7

### 第一部分 原文与翻译

**英文原标题：** CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency.

> **英文摘要：**
> Insufficient functional T cell persistence impedes therapeutic success of chimeric antigen receptor (CAR) therapies. Here we performed a CAR-adapted base-editing screen of PIK3CD, a key regulator of T cell function, metabolism and fate. We identified point mutations that beneficially modulate CAR T cell profiles in 4-1BBz and 28z CAR T cells, respectively. We found that point mutations with differing effects on phosphatidylinositol-3-kinase delta (PI3Kδ) signaling activity were advantageous in distinct CAR contexts: The PI3Kδ-activating substitution E81K enhanced proliferation, metabolic fitness and effector function of 4-1BBz CARs, promoting long-term functional persistence and enhanced therapeutic efficacy in vivo. Conversely, the PI3Kδ-attenuating substitution L32P improved T cell memory formation and functionality of 28z CAR T cells. Together, our approach of rational optimization of activation-dependent signaling through targeted allelic reprogramming (ROADSTAR) illustrates the importance of CAR design-specific fine-tuning of intrinsic T cell signaling and demonstrates the potential of base editing for next-generation cellular therapies.

> **中文摘要：**
> 功能性 T 细胞持续性不足阻碍了嵌合抗原受体（CAR）疗法的治疗成功。在本研究中，我们针对 PIK3CD（一种调控 T 细胞功能、代谢和命运的关键调节因子）进行了 CAR 调适的碱基编辑筛选。我们分别在 4-1BBz 和 28z CAR T 细胞中鉴定出可有益调节其表型的点突变。我们发现，不同影响磷脂酰肌醇-3-激酶 δ（PI3Kδ）信号活性的点突变在不同的 CAR 背景下具有优势：激活型 PI3Kδ 替代突变 E81K 促进了 4-1BBz CAR 的增殖、代谢适应性和效应功能，从而增强体内长期功能持续性与治疗效能。相反，抑制型 PI3Kδ 替代突变 L32P 改善了 28z CAR T 细胞的记忆形成和功能表现。总体而言，我们通过靶向等位基因重编程实现依赖活化信号的合理优化（ROADSTAR）的方法揭示了 CAR 设计特异性对 T 细胞内在信号精细调控的重要性，并展示了碱基编辑在下一代细胞治疗中的潜力。

### 第二部分 AI 大师评价

本研究旨在通过碱基编辑技术优化 PIK3CD 基因来增强 CAR T 细胞的抗肿瘤效能。研究采用 CAR 定制筛选策略，系统评估不同点突变对 T 细胞功能的影响，明确了在不同 CAR 构型下激活型与抑制型 PI3Kδ 突变的差异性优势。结果显著揭示 T 细胞内在信号通路可通过等位基因层面的精准调控实现个性化增强。该研究创新性地将基因编辑与 CAR 设计精细化结合，为下一代细胞疗法提供新方向，但其在临床转化与安全性验证方面仍需进一步探索。

---

## 23. 在精准肿瘤学中超越基因组学的探索

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495412)
**期刊：** Nature medicine
**PMID：** 41495412
**DOI：** 10.1038/s41591-025-04153-0

### 第一部分 原文与翻译

**英文原标题：** Going beyond genomics in precision oncology.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 摘要暂无提供。

### 第二部分 AI 大师评价

该篇发表于《Nature Medicine》的评论或综述性文章，标题指向精准肿瘤学研究正由单纯的基因组层面拓展至更复杂的组学和临床整合方向。其核心理念可能在于强调多维生物学数据（如转录组、蛋白组、代谢组等）与临床信息融合的重要性，以提升肿瘤精准诊治的整体效能。尽管缺乏具体实验或数据，该文概念性地揭示了未来精准医学的趋势与挑战，尤其是如何在基因信息之外进一步实现真正个体化的治疗策略。

---

## 24. 综合基因组分析在晚期实体瘤中的真实世界临床应用价值

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495408)
**期刊：** Nature medicine
**PMID：** 41495408
**DOI：** 10.1038/s41591-025-04086-8

### 第一部分 原文与翻译

**英文原标题：** Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.

> **英文摘要：**
> Comprehensive genomic profiling (CGP) is crucial in precision oncology, yet its real-world utility remains unclear. Here we analyzed data from the Japanese nationwide Center for Cancer Genomics and Advanced Therapeutics database, including clinical and genetic data from 54,185 patients with advanced solid tumors (consisting of 81 common and rare tumor types) who received CGP with a targeted sequencing panel covering 324 genes as part of their clinical care. We assessed the prognostic value of CGP-guided clinical evidence-level classification, showing that alterations predicting response to Pharmaceuticals and Medical Devices Agency-approved or Food and Drug Administration-approved therapies and to therapies supported by well-powered studies with expert consensus are detected in 16.6% and 8.1% of patients, respectively, and are associated with better prognosis than those with lower clinical evidence levels. Only 8% of patients receive CGP-guided approved-experimental genomic biomarker-linked therapies, although the proportion has improved over time. Substantial differences were observed across tumor types, with the proportions exceeding 20% in thyroid and lung cancers but remaining below 2% in pancreatic and liver cancers. Tumor-agnostic biomarker analyses reveal that tumor mutational burden (TMB) ≥20 mutations per megabase predicts better outcome across tumor types, regardless of microsatellite instability status, in TMB-high patients receiving pembrolizumab. Conversely, extramammary Paget's disease is exceptionally resistant to pembrolizumab. The large-scale nationwide database allows evaluating inter-tumor type differences and investigating evidence-scarce situations, delineating where CGP offers greater benefit. These real-world findings complement those from clinical trials and prospective sequencing projects regarding CGP, providing valuable information for individualized treatment.

> **中文摘要：**
> 综合基因组分析（CGP）在精准肿瘤学中具有关键作用，但其真实世界的应用价值仍不清楚。本研究分析了日本全国癌症基因组与先进治疗中心数据库的数据，其中包括54,185例接受CGP检测的晚期实体瘤患者的临床与遗传数据，涵盖81种常见和罕见肿瘤类型，CGP检测采用覆盖324个基因的靶向测序面板作为临床护理的一部分。我们评估了基于CGP的临床证据等级分类的预后价值，结果显示，预测对日本药品医疗器械管理局或美国食品药品监督管理局批准疗法，以及由高质量研究和专家共识支持的疗法产生应答的基因变异，分别在16.6%和8.1%的患者中检测到，这些患者的预后优于具有较低临床证据等级的患者。仅有8%的患者接受基于CGP指导的已批准或实验阶段的基因生物标志物相关治疗，尽管这一比例随着时间推移有所提高。不同肿瘤类型间存在显著差异，其中甲状腺癌和肺癌患者比例超过20%，而胰腺癌和肝癌患者比例低于2%。基于肿瘤无关生物标志物的分析显示，对于TMB ≥20突变/兆碱基的患者，接受帕博利珠单抗治疗时在不同肿瘤类型中均表现出更好的结局，与微卫星不稳定状态无关。相反，乳房外佩吉特病对帕博利珠单抗表现出极强的耐药性。该全国性大型数据库使得能够评估不同肿瘤类型间的差异，并研究证据稀缺的情境，从而明确CGP可带来更大益处的领域。这些真实世界结果补充了关于CGP的临床试验和前瞻性测序项目的发现，为个体化治疗提供了有价值的信息。

### 第二部分 AI 大师评价

该研究利用日本国家级癌症基因组数据库，对超过5万例晚期实体瘤患者的真实世界数据进行了系统分析，探讨综合基因组分析的临床效用。结果揭示CGP指导下的高证据等级基因变异与患者预后改善相关，但整体使用率仍有限。不同肿瘤类型间存在明显异质性，提示精准治疗策略需按肿瘤生物学特征优化。研究创新性地将大规模真实世界数据纳入评估体系，但其局限在于随访时间及治疗可及性因素可能影响结果解释。

---

## 25. 1990–2023年全球、区域及国家层面的慢性呼吸系统疾病负担及其受新冠疫情影响：全球疾病负担研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495401)
**期刊：** Nature medicine
**PMID：** 41495401
**DOI：** 10.1038/s41591-025-04077-9

### 第一部分 原文与翻译

**英文原标题：** Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990-2023: a Global Burden of Disease study.

> **英文摘要：**
> Chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, pneumoconiosis, interstitial lung disease (ILD) and pulmonary sarcoidosis, are major global causes of mortality and morbidity. Although the COVID-19 pandemic has influenced acute respiratory health, its impact on chronic respiratory conditions remains unclear. We estimated the global, regional and national burden of chronic respiratory diseases from 1990 to 2023, including risk factors, and evaluated how these burdens have shifted during the COVID-19 pandemic using the Global Burden of Disease Study 2023. In 2023, chronic respiratory diseases accounted for 569.2 million (95% uncertainty interval (UI), 508.8-639.8) cases and 4.2 million (3.6-5.1) deaths. The age-standardized death rate declined by 25.7% globally from 1990 to 2023 despite an increase in ILD and pulmonary sarcoidosis. Mortality declined in younger males, especially for asthma, whereas older adults experienced a rise in ILD and pulmonary sarcoidosis. Smoking was the primary risk factor for COPD, whereas high body mass index and silica exposure were key risk factors for asthma and pneumoconiosis. During the pandemic, the incidence of chronic respiratory diseases increased modestly, but the decline in mortality rates became more pronounced, highlighting the need for sustained global attention and action to address their long-term burden.

> **中文摘要：**
> 慢性呼吸系统疾病，包括慢性阻塞性肺疾病（COPD）、哮喘、尘肺、间质性肺疾病（ILD）及肺结节病，是全球导致发病率和死亡率的重要原因。尽管新冠疫情对急性呼吸健康造成了影响，但其对慢性呼吸疾病的影响仍不明确。本研究基于2023年全球疾病负担研究，估算了1990年至2023年全球、区域及国家层面的慢性呼吸系统疾病负担及其相关危险因素，并评估这些负担在新冠疫情期间的变化情况。2023年，全球慢性呼吸系统疾病病例数为5.692亿例（95%不确定区间，5.088–6.398亿），死亡人数为420万例（360–510万）。1990年至2023年间，尽管ILD和肺结节病有所增加，但全球年龄标化死亡率仍下降了25.7%。年轻男性的死亡率下降，尤其是哮喘，而老年人群中ILD和肺结节病的死亡呈上升趋势。吸烟是COPD的主要危险因素，而高体重指数和二氧化硅暴露分别是哮喘和尘肺的关键风险因素。在疫情期间，慢性呼吸系统疾病的发病率略有上升，但死亡率下降趋势更为明显，凸显出持续关注与行动以应对其长期负担的必要性。

### 第二部分 AI 大师评价

本研究基于最新的全球疾病负担研究系统性评估了1990–2023年间慢性呼吸系统疾病的全球、区域及国家趋势，并探讨了新冠疫情期间的影响。研究通过大规模流行病学数据揭示出尽管发病有所增加，但总体死亡率显著下降，尤其在年轻男性中更为明显。吸烟、高体重指数及职业性硅暴露等被确认为关键危险因素。该研究的创新在于跨时空比较和疫情期影响分析，但其仍受限于模型估算与数据可得性不均。整体而言，该工作为全球慢性呼吸病防控提供了重要的流行病学依据和政策依据。

---

## 26. 结肠免疫治疗的早期成果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495400)
**期刊：** Nature medicine
**PMID：** 41495400
**DOI：** 10.1038/s41591-025-04143-2

### 第一部分 原文与翻译

**英文原标题：** Early successes in colon immunotherapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文发表于《Nature Medicine》，聚焦结肠免疫治疗领域的最新进展。尽管未提供摘要，但从标题推测，该研究可能总结了结肠癌或炎性肠病免疫治疗的初步临床或实验性成果，展示了免疫策略在结肠疾病管理中的潜力。文章可能强调新疗法的有效性或安全性，为后续大规模研究提供方向。其创新性在于推进免疫治疗在结肠疾病中的早期应用，但仍需更多临床验证以评估持续疗效与广泛适用性。

---

## 27. 碱基编辑的CAR7 T细胞在复发或难治性T细胞急性淋巴细胞白血病中安全且有效。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495241)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41495241
**DOI：** 10.1038/s41571-025-01118-7

### 第一部分 原文与翻译

**英文原标题：** Base-edited CAR7 T cells are safe and efficacious in R/R T-ALL.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究报道了一项关于碱基编辑的CAR7 T细胞在复发或难治性T-ALL患者中的安全性与疗效的临床评估。标题表明该疗法不仅展现出良好的耐受性，还具有显著的抗肿瘤活性。虽然摘要未公布，但从研究方向来看，该研究可能代表T细胞恶性肿瘤免疫治疗的重要进展。其创新在于将碱基编辑技术应用于CAR-T构建，从而克服同源性T细胞靶向的安全风险。局限性可能包括样本量有限或长期随访数据尚不充分。

---

## 28. 基于计算方法的癌症治疗预测性生物标志物的发现

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495240)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41495240
**DOI：** 10.1038/s41571-025-01109-8

### 第一部分 原文与翻译

**英文原标题：** Discovery of predictive biomarkers for cancer therapy through computational approaches.

> **英文摘要：**
> Precision oncology involves the use of predictive biomarkers to personalize treatment. However, for most cancer therapeutics or combination regimens, effective biomarkers have been elusive. This challenge has fuelled efforts to interrogate increasingly diverse and complex clinical and molecular determinants of treatment response. Some molecular predictors have been identified (for example, based on analysis of transcriptomic or imaging data), although the limited reproducibility and robustness of many of these candidate biomarkers make them difficult to apply in clinical practice. Moreover, different types of predictor must often be combined to optimize treatment selection (for example, gene signatures plus patient characteristics). Computational methods, including machine learning and artificial intelligence approaches, provide opportunities to identify predictive patterns in both clinical data and preclinical datasets and to predict treatment response for individual patients. Such approaches also offer opportunities to predict the efficacy or synergy of drug combinations, for example, via extrapolation from correlations of monotherapy responses or by linking the cellular responses observed in preclinical drug screens with molecular and clinical data from patients. In this Review, we describe the application of computational methods to predictive biomarker discovery, including current progress, key challenges facing this field, and future opportunities.

> **中文摘要：**
> 精准肿瘤学涉及利用预测性生物标志物来实现个体化治疗。然而，对于大多数癌症治疗药物或联合治疗方案而言，有效的生物标志物一直难以确定。这一挑战促使研究者不断探究日益多样化且复杂的临床与分子层面治疗反应决定因素。部分分子预测因子已被发现（例如基于转录组或影像数据的分析），但许多候选标志物的可重复性和稳健性有限，使其难以在临床实践中应用。此外，通常需要将不同类型的预测因子相结合以优化治疗选择（例如将基因特征与患者特征结合）。计算方法，包括机器学习和人工智能手段，为在临床数据和临床前数据集中识别预测性模式，以及预测个体患者的治疗反应提供了新的可能性。这些方法还为预测药物组合的疗效或协同作用提供了机会，例如，通过单药反应的相关性外推，或将临床前药物筛选中观察到的细胞反应与患者的分子和临床数据相联系。在本综述中，作者讨论了计算方法在预测性生物标志物发现中的应用，包括当前的进展、该领域面临的关键挑战以及未来的发展机遇。

### 第二部分 AI 大师评价

本文综述了利用计算方法（特别是机器学习与人工智能）发掘癌症治疗预测性生物标志物的最新进展。作者指出在精准肿瘤学中，标志物缺乏可重复性与临床适用性是核心难题。计算方法的引入为融合多维临床与分子数据、揭示个体疗效模式及药物协同规律提供了新契机。该文的创新在于系统梳理了数据驱动预测策略的研究框架与挑战，但同时也指出实现临床转化仍需解决数据异质性与模型可解释性问题。

---

## 29. 用于细胞内靶标结合研究的BRET探针最新进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495225)
**期刊：** Nature chemical biology
**PMID：** 41495225
**DOI：** 10.1038/s41589-025-02103-y

### 第一部分 原文与翻译

**英文原标题：** Advances in BRET probes for intracellular target engagement studies.

> **英文摘要：**
> Assessing drug-target engagement in living cells is essential for verifying the activity of pharmacological agents. Traditional binding assays often overlook key factors such as permeability, intracellular distribution and complex formation that influence target occupancy in cells. Bioluminescence resonance energy transfer (BRET)-based probes enable direct, quantitative assessment of small-molecule binding to proteins in live, intact cells. BRET provides sensitive detection of target engagement across a wide range of target classes, including less-tractable proteins in membrane compartments. Compared to other existing methods, BRET offers quantification of drug occupancy at steady state and open system regimens. Recent innovations in this platform have expanded its utility beyond occupancy confirmation to include applications in polypharmacology and mechanism-of-action studies. Here, we provide an updated perspective on BRET target engagement assays as versatile tools for chemical biology and early-stage drug discovery.

> **中文摘要：**
> 在活细胞中评估药物与靶标的结合是验证药理活性的重要步骤。传统的结合实验往往忽视了诸如渗透性、细胞内分布及复合物形成等影响细胞内靶点占有率的关键因素。基于生物发光共振能量转移（BRET）的探针可在活的、完整的细胞中实现小分子与蛋白质结合的直接且定量的评估。BRET能够灵敏地检测跨不同靶点类别的靶标结合，包括膜区室中较难处理的蛋白质。与其他现有方法相比，BRET能够在稳态及开放体系条件下实现药物占有率的定量测定。该平台的最新创新不仅扩展了其在靶标占有验证方面的应用，还包括多靶药理学及作用机制研究等领域。在此，作者对BRET靶标结合分析作为化学生物学和早期药物发现中多功能工具的最新进展进行了综述与展望。

### 第二部分 AI 大师评价

本文综述了BRET探针在细胞内药物靶标结合测定中的最新进展，强调了其相较于传统方法在活细胞中实现直接、定量检测的优势。文中指出BRET技术能够克服通透性和亚细胞分布等限制，支持不同靶点类别的应用。其新兴的技术改进拓展了用途，涵盖多靶药理学与作用机制研究。整体来看，该研究为化学生物学与早期药物发现提供了重要工具更新，但仍需在复杂生理环境中的定量精确性与通用性方面进一步验证。

---

## 30. 鞘内注射CRISPR编辑的同种异体IL-13Rα2 CAR T细胞用于复发性高级别胶质瘤的研究：临床前特征与I期试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495049)
**期刊：** Nature communications
**PMID：** 41495049
**DOI：** 10.1038/s41467-025-68112-6

### 第一部分 原文与翻译

**英文原标题：** Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial.

> **英文摘要：**
> Patients with recurrent high-grade glioblastoma have a median survival of 6-8 months, with limited therapeutic options. In recent years, interest has grown in applying chimeric antigen receptor T (CAR-T) cells to solid cancers, including advanced gliomas. Here we generated off-the-shelf CRISPR-Cas9-edited IL-13Rα2-specific allogeneic universal CAR-T cells (MT026) by disrupting the endogenous TCR to prevent graft-versus-host disease and knocking out HLA class I molecules to mitigate the host-versus-graft response, and observed minimal NK-cell-mediated rejection in preclinical studies. In a first-in-human, single-center, open-label investigator-initiated trial (ChiCTR2000028801) in patients with high-grade glioma with prior therapy failure and short life expectancy, intrathecal injection of MT026 via lumbar puncture (1.0-3.0×10^7 cells per dose) demonstrated favorable tolerability and safety (primary outcome), pharmacokinetic characteristics, and preliminary clinical activity (secondary outcomes). Among the five patients enrolled, one achieved a complete response and three achieved partial responses. No grade ≥3 adverse events were observed; the predominant treatment-related toxicities were grade 1-2 pyrexia, hypoxia, and vomiting. Trial enrolment was halted after enrolment of the first five patients, however these preliminary clinical data support the potential benefit of locally administered allogeneic universal CAR-T cell therapy for recurrent glioblastoma.

> **中文摘要：**
> 复发性高级别胶质母细胞瘤患者的中位生存期仅为6–8个月，治疗选择有限。近年来，嵌合抗原受体T（CAR-T）细胞在包括晚期胶质瘤在内的实体瘤中的应用引起了越来越多的关注。本研究中，我们通过敲除内源性TCR以预防移植物抗宿主病，并敲除HLA I类分子以减轻宿主抗移植物反应，构建了即用型CRISPR-Cas9编辑的IL-13Rα2特异性同种异体通用CAR-T细胞（MT026），并在临床前研究中观察到极低的NK细胞介导的排斥反应。在一项针对既往治疗失败且预期寿命较短的高级别胶质瘤患者的首次人体、单中心、开放标签、研究者发起的临床试验（ChiCTR2000028801）中，经腰椎穿刺进行MT026鞘内注射（每剂1.0–3.0×10^7个细胞）显示出良好的耐受性和安全性（主要结局），以及药代动力学特征和初步的临床活性（次要结局）。在5名入组患者中，1例获得完全缓解，3例获得部分缓解。未观察到≥3级不良事件；主要治疗相关毒性为1–2级发热、低氧和呕吐。尽管试验在入组5名患者后即停止，但这些初步临床数据支持局部给药的同种异体通用CAR-T细胞疗法在复发性胶质母细胞瘤治疗中的潜在益处。

### 第二部分 AI 大师评价

本研究旨在探索CRISPR编辑的IL-13Rα2靶向同种异体通用CAR-T细胞在复发性高级别胶质瘤中的治疗潜力。研究团队通过敲除TCR和HLA I类分子减少免疫排斥，并采用鞘内注射的局部给药策略。I期试验结果显示良好的安全性及初步的临床疗效，部分患者出现显著肿瘤缓解。该研究在同类免疫细胞治疗中具有创新性，展示了离体即用型CAR-T细胞治疗脑肿瘤的可行性，但样本量有限仍需进一步验证疗效与长期安全性。

---

## 31. 深度学习引导的蛋白酶底物设计

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495045)
**期刊：** Nature communications
**PMID：** 41495045
**DOI：** 10.1038/s41467-025-67226-1

### 第一部分 原文与翻译

**英文原标题：** Deep learning guided design of protease substrates.

> **英文摘要：**
> Proteases, enzymes that play critical roles in health and disease, exert their function through the cleavage of peptide bonds. Identifying substrates that are efficiently and selectively cleaved by target proteases is essential for studying protease activity and for harnessing it in protease-activated diagnostics and therapeutics. However, the vast design space of possible substrates (c.a. 20 amino acid combinations for a 10-mer peptide) and the limited accessibility of high-throughput activity profiling tools hinder the speed and success of substrate design. We present CleaveNet, an end-to-end AI pipeline for the design of protease substrates. Applied to matrix metalloproteinases, CleaveNet enhances the scale, tunability, and efficiency of substrate design. CleaveNet generates peptide substrates that exhibit sound biophysical properties and capture not only well-established but also previously-uncharacterized cleavage motifs. To control substrate design, CleaveNet incorporates a conditioning tag that steers peptide generation towards desired cleavage profiles, enabling targeted design of efficient and selective substrates. CleaveNet-generated substrates were validated experimentally through a large-scale in vitro screen, even in the challenging case of designing highly selective substrates for MMP13. We envision that CleaveNet will accelerate our ability to study and capitalize on protease activity, paving the way for in silico design tools across enzyme classes.

> **中文摘要：**
> 蛋白酶作为在健康与疾病中发挥关键作用的酶类，其功能通过切割肽键来实现。识别能够被目标蛋白酶高效且特异性切割的底物对于研究蛋白酶活性以及在蛋白酶激活型诊断与治疗中加以利用至关重要。然而，潜在底物的巨大设计空间（例如，一个10肽的约20个氨基酸组合）以及高通量活性分析工具的有限可获取性，限制了底物设计的速度和成功率。我们提出了CleaveNet，这是一个用于蛋白酶底物设计的端到端人工智能流程。应用于基质金属蛋白酶时，CleaveNet提升了底物设计的规模性、可调性和效率。CleaveNet生成的肽底物具有良好的生物物理性质，不仅能够捕捉既有的、且能发现此前未表征的切割基序。为实现底物设计的可控性，CleaveNet引入了一个条件标签，以引导肽序列生成朝向目标切割特征，从而实现高效且选择性底物的定向设计。通过大规模体外筛选，CleaveNet生成的底物得到了实验验证，即便在设计对MMP13具有高度选择性的底物这一挑战性情境下也表现出良好性能。我们预期，CleaveNet将加速我们对蛋白酶活性的研究与利用，为跨酶种类的计算设计工具铺平道路。

### 第二部分 AI 大师评价

该研究旨在开发并验证一种基于深度学习的蛋白酶底物设计平台CleaveNet。作者利用端到端AI建模，实现了从序列生成到特征调控的智能化底物设计流程，并在基质金属蛋白酶系统中验证了其可扩展性和选择性。研究不仅揭示了新的潜在切割基序，还在高难度的MMP13底物设计中取得成功。该工作创新性在于将条件生成模型引入蛋白酶底物设计领域，为酶工程提供了可推广的计算策略，但其模型泛化性及在其他酶类中的适用性仍需进一步验证。

---

## 32. 异柠檬酸脱氢酶1突变导致急性髓系白血病中IL1R1下调及炎症反应失调。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495035)
**期刊：** Blood cancer journal
**PMID：** 41495035
**DOI：** 10.1038/s41408-025-01445-z

### 第一部分 原文与翻译

**英文原标题：** Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemia.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究聚焦于异柠檬酸脱氢酶1（IDH1）突变在急性髓系白血病（AML）中的分子机制，揭示其可能通过下调白细胞介素-1受体1（IL1R1）影响细胞炎症反应。尽管摘要未公开内容，但从标题可推测研究利用分子或转录学分析探讨突变对免疫调控通路的影响。该工作提示IDH1突变不仅调节代谢，还可能介入免疫微环境调控，为AML靶向治疗提供新的方向。然而，具体机制与临床转化价值仍有待进一步验证。

---

## 33. 通过 AZD0466 实现的双重 Bcl-2/Bcl-xl 抑制联合免疫检查点阻断可增强抗肿瘤活性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495028)
**期刊：** Cell death & disease
**PMID：** 41495028
**DOI：** 10.1038/s41419-025-08354-w

### 第一部分 原文与翻译

**英文原标题：** Dual Bcl-2/Bcl-xl inhibition via AZD0466 combines with immune checkpoint blockade to enhance anti-tumour activity.

> **英文摘要：**
> Small molecule inhibitors designed to specifically target oncogenic proteins have demonstrated potent anti-tumour activities due to direct effects on tumour cells survival and/or proliferation. However, the effects of these compounds on normal cells, specifically immune cells and their potential to impede or enhance anti-cancer immunotherapies has yet to be fully explored. Using an in vitro co-culture system to assess CD8+ T cell killing of tumour cells, we identified compounds that inhibit Bcl-2 and Bcl-xl as agents that can induce tumour cell death without impacting the differentiation or function of anti-tumour T cells. Accordingly, in vivo treatment of mice bearing solid tumours with a combination of the Bcl-2/Bcl-xl inhibitor AZD0466 and anti-PD-L1 immunotherapy resulted in enhanced anti-tumour effects and improved survival compared to equivalent monotherapies.

> **中文摘要：**
> 专为靶向致癌蛋白设计的小分子抑制剂因其对肿瘤细胞存活和/或增殖的直接作用，已显示出强大的抗肿瘤活性。然而，这些化合物对正常细胞，尤其是免疫细胞的影响，以及其可能抑制或增强抗癌免疫治疗的潜力，尚未被充分研究。利用体外共培养系统评估 CD8+ T 细胞对肿瘤细胞的杀伤作用，我们鉴定出抑制 Bcl-2 和 Bcl-xl 的化合物，可诱导肿瘤细胞死亡，而不影响抗肿瘤 T 细胞的分化或功能。因此，在携带实体瘤的小鼠中联合使用 Bcl-2/Bcl-xl 抑制剂 AZD0466 与抗 PD-L1 免疫治疗，与单药治疗相比，表现出更强的抗肿瘤效应和更好的生存获益。

### 第二部分 AI 大师评价

本研究旨在探讨双重 Bcl-2/Bcl-xl 抑制剂 AZD0466 与免疫检查点阻断疗法联合的抗肿瘤潜力。作者利用体外 CD8+ T 细胞共培养体系和体内小鼠实体瘤模型，显示该组合既能诱导肿瘤细胞死亡，又不损害抗肿瘤 T 细胞功能。结果表明 AZD0466 可增强抗 PD-L1 治疗的效果并改善生存。研究创新性在于揭示了 Bcl-2/Bcl-xl 靶向策略与免疫疗法的协同作用，但仍需进一步验证其临床转化的安全性与有效性。

---

## 34. 癌前病变的信号通路及靶向干预策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495021)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41495021
**DOI：** 10.1038/s41392-025-02342-4

### 第一部分 原文与翻译

**英文原标题：** Signaling pathways and targeted interventions for precancers.

> **英文摘要：**
> Precancers, defined as normal-appearing or morphologically altered tissues with a risk of oncogenesis, exhibit various detectable manifestations across anatomical sites, including epithelial dysplasia, metaplasia, hyperplasia, and stromal fibrosis. Considering the prevailing assumption that most cancers arise from precancers, early intervention at the precancerous stage has immense potential to reduce cancer-related morbidity and mortality. However, the complex signaling networks governing precancer initiation and progression remain elusive, hampering the development of effective targeted interventions. This review synthesizes three critical dimensions of precancer biology: historical foundations tracing the conceptual evolution of precancer research over the past century; mechanisms underlying the multistep progression of precancer biology, encompassing epithelial and macro/microenvironmental remodeling; and signaling networks cataloging dysregulated pathways and their therapeutic potential. Over 10 signaling pathways, including the transforming growth factor-β (TGF-β), p53, Wnt, phosphatidylinositol 3-kinase (PI3K), and mitogen-activated protein kinase (MAPK) pathways, drive multistep malignant transformation. We further synthesize emerging evidence supporting microenvironmental dominance, proposing the novel "soil degeneration" hypothesis. This paradigm shift underscores the necessity for dual-window intervention in which early-phase microenvironmental normalization prevents the establishment of precancerous lesions and advanced-phase treatment concurrently addresses epithelial malignancy and stromal degeneration. This review bridges foundational molecular discoveries with translational clinical potential and advocates for precision intervention frameworks that extend from biomarker-guided risk assessment to synergistic remodeling of the precancer microenvironment, thereby redefining precancer intervention in the molecularly targeted era.

> **中文摘要：**
> 癌前病变被定义为外观正常或形态学上改变但具有肿瘤发生风险的组织，在不同解剖部位表现出多种可检测的形态，如上皮发育不良、化生、增生和基质纤维化。鉴于大多数癌症被认为起源于癌前病变，早期在癌前阶段进行干预具有巨大的潜力，可显著减少与癌症相关的发病率和死亡率。然而，调控癌前病变起始与进展的复杂信号网络仍不清晰，阻碍了有效靶向干预策略的发展。本综述整合了癌前生物学的三个关键维度：其一是历史基础，追溯过去一个世纪癌前研究理念的演变；其二是癌前病变多步进展的机制，包括上皮及宏观/微观环境的重塑；其三是信号网络，总结了失调的通路及其治疗潜力。包括转化生长因子β（TGF-β）、p53、Wnt、磷脂酰肌醇-3-激酶（PI3K）和有丝分裂原活化蛋白激酶（MAPK）等在内的10余条信号通路共同驱动多阶段的恶性转化。我们进一步综合了支持微环境主导作用的新兴证据，并提出了新的“土壤退化”假说。这一范式转变强调了“双窗口干预”的必要性，即早期阶段的微环境正常化可防止癌前病变的建立，而晚期治疗应同时解决上皮恶变与基质退化问题。本综述连接了基础分子发现与临床转化潜能，倡导从生物标志物引导的风险评估到协同重塑癌前微环境的精准干预框架，从而在分子靶向时代重新定义癌前病变干预。

### 第二部分 AI 大师评价

该综述系统阐述了癌前病变的信号通路与干预策略，回顾了百年来相关概念的演进，并梳理了多步恶变过程中的上皮及微环境重塑机制。文章重点整合了十余条关键信号通路及其在癌前转化中的作用，提出了具有创新意义的“土壤退化”假说及“双窗口干预”思路。该研究的创新性在于将基础信号研究与微环境调控视角相结合，构建了癌前干预的精准化框架，但其理论仍需更多实验与临床验证以确立可行性。

---

## 35. 深度学习辅助发现RNA N-甲基腺苷识别蛋白YTHDC2的高效细胞活性抑制剂

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495018)
**期刊：** Nature communications
**PMID：** 41495018
**DOI：** 10.1038/s41467-025-65542-0

### 第一部分 原文与翻译

**英文原标题：** Deep learning-assisted discovery of a potent and cell-active inhibitor of RNA N-methyladenosine recognition protein YTHDC2.

> **英文摘要：**
> YTHDC2, a unique YTH-domain-containing protein that recognizes N6-methyladenosine (mA) on RNA, plays critical roles in diverse pathological processes and represents a promising therapeutic target. Despite its potential, no potent small-molecule inhibitors have been reported to date. To bridge this gap, we develop EPMolGen, a deep learning-based molecular generative model that explicitly incorporates the electrostatic features of receptor proteins. The model achieves state-of-the-art performance in dry-lab validations. Using EPMolGen, we identify H3, a YTHDC2 inhibitor with an IC of 16.84 μM. Subsequent structural optimization of H3 yields DC2-C1, a highly potent compound with an IC of 0.168 μM against YTHDC2 and selectivity over other YTH-domain proteins. In cellular assays, DC2-C1 effectively targets YTHDC2. Notably, DC2-C1 treatment substantially reduces the expression levels of multiple target mRNAs of YTHDC2, leading to phenotypic suppression of related cells. Overall, this study highlights the great potential of deep learning in drug discovery and provides a promising lead compound for drug development targeting YTHDC2.

> **中文摘要：**
> YTHDC2是一种能够识别RNA上N6-甲基腺苷（mA）的独特YTH结构域蛋白，在多种病理过程中发挥关键作用，并被认为是一个有前景的治疗靶点。尽管其潜力巨大，但目前尚未报道有效的小分子抑制剂。为填补这一空白，我们开发了EPMolGen，一种基于深度学习的分子生成模型，能够显式整合受体蛋白的静电特征。该模型在干实验验证中表现出领先的性能。通过EPMolGen，我们鉴定出H3，这是一种YTHDC2抑制剂，其IC值为16.84 μM。进一步对H3进行结构优化后得到DC2-C1，这是一种对YTHDC2具有极高效力且对其他YTH结构域蛋白具有选择性的化合物，其IC值为0.168 μM。在细胞实验中，DC2-C1能够有效靶向YTHDC2。值得注意的是，DC2-C1处理显著降低了多个YTHDC2靶mRNA的表达水平，从而导致相关细胞表型的抑制。总体而言，本研究展示了深度学习在药物发现中的巨大潜力，并为靶向YTHDC2的药物开发提供了一个有前景的先导化合物。

### 第二部分 AI 大师评价

该研究旨在利用深度学习模型EPMolGen推动YTHDC2抑制剂的发现，通过引入蛋白静电特征实现了生成模型的创新优化。结果识别出高效的小分子DC2-C1，其在体外和细胞水平均表现出良好的靶向活性和选择性。研究不仅验证了深度学习在药物生成中的应用潜力，还提供了YTHDC2靶向治疗的化学起点。其局限在于目前验证仍以干实验和细胞水平为主，仍需进一步的动物及临床验证。

---

## 36. 复发难治性多发性骨髓瘤中外周血免疫细胞特征分析及其对BCMA CAR-T细胞治疗的反应。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495017)
**期刊：** Blood cancer journal
**PMID：** 41495017
**DOI：** 10.1038/s41408-025-01443-1

### 第一部分 原文与翻译

**英文原标题：** Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究聚焦于复发或难治性多发性骨髓瘤患者，旨在通过外周血免疫细胞群特征分析探讨BCMA CAR‑T细胞治疗的应答差异。尽管摘要缺失，标题暗示研究可能利用高维免疫学分析（如流式细胞术或单细胞测序）评估治疗前后免疫微环境变化。该方向具有重要的临床价值，可为预测疗效与优化CAR‑T疗法提供免疫学指标。然而，若缺乏系统性纵向采样或功能验证，结果的泛化性可能受限。

---

## 37. 涉及乳头的大型（≥3 cm）横向扩展性十二指肠肿瘤行内镜黏膜下剥离术的可行性：一项多中心回顾性研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41494809)
**期刊：** Gut
**PMID：** 41494809
**DOI：** 10.1136/gutjnl-2025-336411

### 第一部分 原文与翻译

**英文原标题：** Feasibility of endoscopic submucosal dissection for large (≥3 cm) laterally spreading duodenal tumours involving the papilla: a multicentre retrospective study.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

本研究旨在探讨内镜黏膜下剥离术（ESD）治疗涉及乳头的巨大横向扩展性十二指肠肿瘤的可行性。通过多中心回顾性分析，作者可能评估手术成功率、安全性与并发症情况，从而填补该领域的临床证据空白。研究的创新性在于聚焦少见且技术挑战较大的病变类型。其局限性可能包括样本量有限、回顾性设计及操作依赖性较强。整体而言，该研究为复杂十二指肠病变的内镜治疗策略提供了重要参考。

---

## 38. 新辅助放化疗后低位直肠癌“观察与等待”策略的优化：内镜下全层切除的初步研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41494805)
**期刊：** Gut
**PMID：** 41494805
**DOI：** 10.1136/gutjnl-2025-336549

### 第一部分 原文与翻译

**英文原标题：** Refining watch-and-wait in low rectal cancer after neoadjuvant chemoradiotherapy: pilot study of endoscopic full-thickness resection.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可供参考。

### 第二部分 AI 大师评价

该研究聚焦于新辅助放化疗后低位直肠癌的“观察与等待”策略优化，尝试以内镜下全层切除技术作为补充或验证手段。这种探索性研究旨在改善临床评估的精确性，并在保留肛门功能与避免过度治疗之间寻求平衡。尽管仅为试点研究，但其方法学创新性值得关注；然而，样本量与随访结果可能限制了结论的外推性。

---

## 39. 综合筛选揭示通过靶向IMPDH2导致的鸟嘌呤核苷酸消耗具有不可逆性，可抑制胰腺癌并增强KRAS抑制效果。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41494804)
**期刊：** Gut
**PMID：** 41494804
**DOI：** 10.1136/gutjnl-2025-336235

### 第一部分 原文与翻译

**英文原标题：** Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition.

> **英文摘要：**
> BACKGROUND: Over 90% pancreatic cancers harbour activating kirsten rat sarcoma viral oncogene homolog (KRAS）mutations. However, monotherapies targeting the KRAS vertical pathway, with recently developed KRAS inhibitors or rapidly accelerated fibrosarcoma (RAF)/MEK/ERK inhibitors, have demonstrated limited clinical benefit. Therefore, there is an urgent need to identify novel therapeutic targets and combination strategies with KRAS inhibition.
> 
> OBJECTIVE: This study aims to identify pharmaceutical targets whose inhibition suppresses pancreatic ductal adenocarcinoma (PDAC) or potentiates KRAS inhibition, focusing on molecular vulnerabilities specific to KRAS-mutant PDAC.
> 
> DESIGNS: We integrated genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 (CRISPR-associated Protein 9) dropout screens, large-scale genomic dependency datasets and pharmacological screens to identify molecular vulnerabilities in KRAS-mutant PDAC. Conditional knockout mouse models were used to assess the essentiality of candidate genes in pancreatic cancer. RNA sequencing, metabolomics/proteomics analysis and stable isotopic tracing were employed to investigate mechanisms underlying inosine monophosphate dehydrogenase 2 (IMPDH2) vulnerability. Additionally, proteolysis-targeting chimaera compounds targeting IMPDH2 were developed and evaluated in patient-derived organoid and xenograft models.
> 
> RESULTS: Integrated screens revealed de novo guanine nucleotide biosynthesis (DNGB) as a vulnerability in KRAS-mutant PDAC, with  being the critical gene. Unexpectedly, IMPDH2 expression and activity are not driven by the KRAS vertical pathway. Consequently, IMPDH2 inhibition induces irreversible guanine nucleotide depletion that cannot be compensated for by mutant KRAS. Inducing guanine nucleotide depletion via targeting IMPDH2 for degradation inhibits PDAC and augments KRAS inhibitor efficacy in vitro and in vivo.
> 
> CONCLUSIONS: These findings provide a rationale for developing combination therapies targeting KRAS and DNGB, highlighting the potential of purine nucleotide imbalance as a biomarker to guide the application of these therapies.

> **中文摘要：**
> 背景：超过90%的胰腺癌存在激活型的Kirsten大鼠肉瘤病毒同源癌基因（KRAS）突变。然而，针对KRAS垂直通路的单药治疗（包括近年来开发的KRAS抑制剂或RAF/MEK/ERK抑制剂）仅显示出有限的临床获益。因此，迫切需要发现新的治疗靶点及与KRAS抑制联合的策略。
> 
> 研究目的：本研究旨在寻找抑制后可抑制胰腺导管腺癌（PDAC）或增强KRAS抑制作用的药物学靶点，重点关注KRAS突变型PDAC特有的分子脆弱性。
> 
> 研究设计：我们整合了全基因组CRISPR/Cas9脱落筛选、大规模基因依赖性数据库及药理学筛选，以识别KRAS突变型PDAC中的分子脆弱性。采用条件性敲除小鼠模型评估候选基因在胰腺癌中的必需性。通过RNA测序、代谢组学/蛋白质组学分析以及稳定同位素示踪研究IMPDH2（次黄嘌呤单磷酸脱氢酶2）脆弱性的机制。此外，还开发了靶向IMPDH2的蛋白降解诱导嵌合物化合物，并在患者来源的类器官及异种移植模型中进行评价。
> 
> 研究结果：综合筛选结果显示，KRAS突变型PDAC对新生鸟嘌呤核苷酸生物合成（DNGB）途径存在依赖，其中IMPDH2是关键基因。出乎意料的是，IMPDH2的表达和活性并非由KRAS垂直通路驱动。因此，抑制IMPDH2会诱导不可逆的鸟嘌呤核苷酸消耗，而这种消耗无法通过突变型KRAS补偿。通过靶向IMPDH2促使其降解诱导鸟嘌呤核苷酸枯竭，可在体内外抑制PDAC并增强KRAS抑制剂的疗效。
> 
> 结论：这些发现为联合靶向KRAS与DNGB通路的治疗方案提供了理论依据，并指出嘌呤核苷酸失衡有望作为指导该类疗法应用的生物标志物。

### 第二部分 AI 大师评价

该研究针对KRAS突变型胰腺导管腺癌的分子脆弱性进行了系统性挖掘，通过整合CRISPR筛选、基因依赖数据及药物筛选，鉴定出IMPDH2及新生鸟嘌呤核苷酸合成通路为关键脆弱点。作者发现IMPDH2抑制可引起不可逆的核苷酸枯竭，独立于KRAS信号通路，从而显著增强KRAS抑制剂效应。研究创新性在于揭示胰腺癌中嘌呤代谢依赖的新机制，并为联合代谢与信号通路抑制提供潜在策略。局限性在于仍需在临床前和临床研究中验证疗效与安全性。

---

## 40. 靶向MLCK1可将免疫检查点抑制剂诱导的结肠炎与抗肿瘤免疫分离。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41494803)
**期刊：** Gut
**PMID：** 41494803
**DOI：** 10.1136/gutjnl-2025-337780

### 第一部分 原文与翻译

**英文原标题：** Targeting MLCK1 uncouples immune checkpoint inhibitor-induced colitis from antitumour immunity.

> **英文摘要：**
> OBJECTIVE: Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment and patients' survival. However, ICIs also cause severe immune-related adverse events, notably colitis, resulting in ICIs therapy discontinuation and tumour immunotherapy failure. This study investigates long myosin light chain kinase 1 (MLCK1), a known regulator of tight junction and gut permeability, to elucidate the mechanisms underlying ICI-mediated colitis and identify approaches to reduce this toxicity.
> 
> DESIGN: This study employed an integrated approach, using clinical samples, in vivo models and in vitro organoid systems. Biopsies from patients with ICIs colitis were profiled using single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics. To recapitulate human ICIs colitis, we used a wild mouse microbiota (WildR) model, alongside various genetically modified and tumour-bearing models (including melanoma and MC38). Furthermore, mechanisms were investigated through organoid-immune cell co-cultures. Finally, surface plasmon resonance, microscale thermophoresis, full-spectrum flow cytometry, bulk RNA sequencing, immunostaining, ELISA and gut permeability assays were performed to comprehensively delineate the underlying molecular mechanism.
> 
> RESULTS: Tight junction integrity was compromised in both human ICIs colitis and our WildR mouse model. We determined that this barrier dysfunction is driven by activation of the MLCK1-mediated leak pathway following ICI treatment. Using murine models, we identified tumour necrosis factor secreted by CD8 and CD4 T cells as an upstream regulator that induces colitis through this MLCK-dependent mechanism, as genetic deletion of MLCK preserved the tight junction structure and ameliorated the inflammation and ICIs colitis. Furthermore, a pharmacological screen identified the small molecule Epicatechin, which blocks MLCK1-FKBP8 interaction and inhibits the recruitment of MLCK1 to the perijunctional actomyosin ring and prevents the intestinal barrier loss. Finally, treatment with Epicatechin mitigated ICI-induced colitis without compromising the antitumour efficacy of the immunotherapy.
> 
> CONCLUSIONS: These findings suggest that MLCK1-dependent tight junction regulation is essential for ICIs colitis, positioning barrier restoration as a potential therapeutic strategy.

> **中文摘要：**
> 研究目的：免疫检查点抑制剂（ICIs）已经彻底改变了癌症治疗和患者生存。然而，ICIs 也会引发严重的免疫相关不良事件，尤其是结肠炎，从而导致 ICIs 治疗中断及肿瘤免疫治疗失败。本研究旨在探讨长型肌球蛋白轻链激酶1（MLCK1）这一紧密连接及肠道通透性调控因子，以阐明ICIs诱导结肠炎的机制，并寻找降低该毒性的方法。
> 
> 研究设计：本研究采用综合研究策略，结合临床样本、体内动物模型及体外类器官体系。对ICIs相关结肠炎患者的活检样本进行单细胞RNA测序（scRNA-seq）及空间转录组学分析。为重现人类ICIs结肠炎，我们采用野生鼠群微生物群（WildR）模型，并结合多种基因修饰及肿瘤负荷模型（包括黑色素瘤与MC38）。此外，通过类器官-免疫细胞共培养探究其机制。最后，运用表面等离子共振、微尺度热泳动、全谱流式细胞术、整体RNA测序、免疫染色、ELISA及肠道通透性实验，全面描绘其分子机制。
> 
> 研究结果：无论在人类ICIs结肠炎还是野生鼠WildR模型中，紧密连接的完整性均受到损害。我们发现，该屏障功能障碍由ICIs治疗后MLCK1介导的渗漏通路激活所驱动。利用小鼠模型，我们确定CD8和CD4 T细胞分泌的肿瘤坏死因子（TNF）作为上游调节因子，通过MLCK依赖机制诱导结肠炎；而MLCK基因敲除可保持紧密连接结构，减轻炎症并改善ICIs结肠炎。此外，药理筛选发现小分子表儿茶素（Epicatechin）可阻断MLCK1-FKBP8相互作用，抑制MLCK1向连接周环肌动蛋白环募集，从而防止肠道屏障丧失。最后，表儿茶素治疗可减轻ICIs诱导的结肠炎，而不影响免疫治疗的抗肿瘤效应。
> 
> 研究结论：研究结果表明，MLCK1依赖的紧密连接调控在ICIs结肠炎中起关键作用，提示通过恢复屏障功能可作为潜在的治疗策略。

### 第二部分 AI 大师评价

本研究揭示了免疫检查点抑制剂相关结肠炎的关键分子机制，即通过MLCK1介导的紧密连接失调导致肠屏障功能受损。研究团队利用临床、动物及类器官多层验证，展示了TNF通过MLCK通路驱动炎症的过程，并发现表儿茶素可阻断该通路，改善结肠炎而不影响抗肿瘤免疫。这一成果为降低免疫毒性、优化免疫治疗耐受性提供了新的治疗思路。其创新性体现在从屏障生物学视角切入免疫副作用机制，局限性在于仍需更大规模临床验证。

---

## 41. 肿瘤内树突状细胞免疫治疗可控制转移起始癌细胞的扩散，即使在转移性乳腺癌患者中亦然。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41494747)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41494747
**DOI：** 10.1136/jitc-2025-013590

### 第一部分 原文与翻译

**英文原标题：** Intratumoral dendritic cell immunotherapy controls dissemination of metastasis-initiating cancer cells, even in patients with metastatic breast cancer.

> **英文摘要：**
> Patients with metastatic breast cancer (MBC) have limited opportunities for a cure, as they develop resistance to therapies and continually form new metastases. Clinical overt metastases emerge from metastasis-initiating cancer cells (MICs) that disseminate during breast cancer (BC) progression. Currently, there are no available therapies that inhibit MIC dissemination to prevent overt metastasis. We provide preclinical evidence that intratumoral (IT) delivery of type I polarized dendritic cells (DC1) limited the MIC dissemination mechanisms in tumor lesions of human epidermal growth factor receptor 2 (HER2)+ mammary carcinoma. Interferon gamma, a prominent cytokine secreted by T helper 1 and innate-like immune effector cells, inhibited dissemination of MICs from the tumor lesions via the modulation of HER2/progesterone receptor/Wnt family member 4/receptor activator of nuclear factor kappa beta ligand signaling. Importantly, we provide clinical evidence that in patients with stage I-III HER2+ BC, there was significant regression of the primary tumor treated with IT DC1, as well as inhibition of disseminating MIC phenotypes. We observed a reduced burden of MICs in the bone marrow (BM) of patients with stage I-III HER2+BC treated with IT DC1, compared with untreated patients and those treated with standard neoadjuvant HER2 therapies paclitaxel, with or without carboplatin, trastuzumab and pertuzumab (Taxol, Carboplatin, Herceptin and Perjeta or THP). We also treated a single patient with de novo stage IV HER2+ MBC with trastuzumab, pertuzumab and tamoxifen in combination with IT DC1. Remarkably, this treatment resulted in near-complete regression of primary tumor and metastatic disease, along with inhibition of MIC seeding in the BM. These findings suggest an intriguing strategy to inhibit the dissemination of MICs and prevent further overt metastasis in all patients with BC.

> **中文摘要：**
> 转移性乳腺癌（MBC）患者治愈机会有限，因为她们会对治疗产生耐药性并持续形成新的转移灶。临床上显性的转移源自乳腺癌（BC）进展过程中扩散的转移起始癌细胞（MICs）。目前尚无可抑制 MIC 扩散、以防止显性转移的治疗手段。我们提供了临床前证据，显示肿瘤内（IT）输注I型极化树突状细胞（DC1）可限制人类表皮生长因子受体 2（HER2）阳性乳腺癌病灶中 MIC 扩散的机制。由辅助性T细胞1型（Th1）及类固有免疫效应细胞分泌的重要细胞因子——干扰素γ，通过调节 HER2/孕激素受体/Wnt家族成员4/核因子κB受体活化配体信号通路，抑制了肿瘤病灶中 MIC 的扩散。重要的是，我们提供了临床证据，在 I–III 期 HER2 阳性 BC 患者中，经 IT DC1 治疗后，原发肿瘤显著回缩，且 MIC 扩散表型受到抑制。与未经治疗或接受标准新辅助 HER2 靶向疗法（紫杉醇±卡铂、曲妥珠单抗及帕妥珠单抗，即 THP）者相比，接受 IT DC1 治疗的 I–III 期 HER2 阳性 BC 患者的骨髓（BM）中 MIC 负荷显著降低。我们还治疗了一例新发 IV 期 HER2 阳性 MBC 患者，采用曲妥珠单抗、帕妥珠单抗及他莫昔芬联合 IT DC1。值得注意的是，该治疗几乎使原发灶及转移病变完全回归，同时抑制了 MIC 在骨髓中的定植。这些发现提示了一种有前景的策略，可用于抑制 MIC 的扩散并防止所有乳腺癌患者进一步显性转移的发生。

### 第二部分 AI 大师评价

该研究通过临床前和初步临床数据表明，肿瘤内注射I型极化树突状细胞可通过干扰IFN-γ介导的信号通路抑制转移起始癌细胞的扩散。该疗法在HER2阳性乳腺癌患者中显著减少了骨髓MIC负荷并促进肿瘤回缩，甚至在晚期转移患者中也显示出令人瞩目的疗效。研究创新性地提出了直接靶向MIC扩散的免疫治疗策略。然而，样本量有限且需进一步大规模临床验证其长期疗效与安全性。

---

## 42. 癌症幸存者焦虑的远程音乐治疗与认知行为治疗比较：一项随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41494146)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41494146
**DOI：** 10.1200/JCO-25-00726

### 第一部分 原文与翻译

**英文原标题：** Music Therapy Versus Cognitive Behavioral Therapy via Telehealth for Anxiety in Cancer Survivors: A Randomized Clinical Trial.

> **英文摘要：**
> PURPOSE: Anxiety is prevalent, disruptive, and undertreated among cancer survivors. Cognitive behavioral therapy (CBT) is the first-line treatment, but not all individuals have access, respond to treatment, or prefer this option because of stigma. Music therapy is effective for short-term anxiety reduction, but it is unknown whether it is noninferior to first-line CBT for long-term anxiety reduction.
> 
> METHODS: This comparative effectiveness trial randomly assigned English- or Spanish-speaking cancer survivors to seven weekly telehealth sessions of music therapy or CBT. The coprimary end points were changes in the Hospital Anxiety and Depression Scale (HADS) anxiety score at weeks 8 and 26. The noninferiority margin was 0.35 standard deviations, informed by a minimal clinically important difference (MCID) of 1.7 points. Secondary outcomes included fatigue, depression, insomnia, pain, cognitive dysfunction, and health-related quality of life.
> 
> RESULTS: Among N = 300 patients, 74.7% was female, 76.5% was White, and 19.0% was Hispanic. At week 8, the mean change in HADS anxiety score was -3.12 (95% CI, -3.59 to -2.65) in music therapy and -2.97 (95% CI, -3.45 to -2.50) in CBT; the between-group difference was -0.15 (95% CI, -0.78 to 0.49), within the noninferiority margin of 1.20 ( < .001). At week 26, the mean change was -3.31 (95% CI, -3.78 to -2.85) in music therapy and -3.00 (95% CI, -3.47 to -2.53) in CBT; the between-group difference was -0.31 (95% CI, -0.95 to 0.32), within the noninferiority margin of 1.28 ( < .001). Both groups produced anxiety reductions exceeding the MCID and showed similar improvements in secondary outcomes.
> 
> CONCLUSION: Music therapy is noninferior to CBT for anxiety in cancer survivors. Both telehealth interventions produced clinically meaningful, durable improvements in anxiety.

> **中文摘要：**
> 研究目的：焦虑在癌症幸存者中常见、干扰性强且治疗不足。认知行为疗法（CBT）是首选治疗，但并非所有人都能获得此种治疗、对治疗有反应或因社会污名而偏好此方法。音乐治疗对短期焦虑减轻有效，但其在长期焦虑缓解方面是否不劣于一线CBT尚不清楚。
> 
> 研究方法：本项比较有效性试验将讲英语或西班牙语的癌症幸存者随机分配至音乐治疗组或CBT组，接受7次每周一次的远程治疗课程。共同主要终点为第8周和第26周医院焦虑抑郁量表（HADS）焦虑评分的变化。不劣性界值设为0.35个标准差，参照最小临床重要差异（MCID）为1.7分确定。次要结局包括疲劳、抑郁、失眠、疼痛、认知功能障碍及与健康相关的生活质量。
> 
> 研究结果：在共300名受试者中，女性占74.7%，白人占76.5%，西班牙裔占19.0%。第8周时，音乐治疗组HADS焦虑评分平均变化为-3.12（95% CI，-3.59至-2.65），CBT组为-2.97（95% CI，-3.45至-2.50）；组间差异为-0.15（95% CI，-0.78至0.49），在不劣性界值1.20以内（P < .001）。第26周时，音乐治疗组平均变化为-3.31（95% CI，-3.78至-2.85），CBT组为-3.00（95% CI，-3.47至-2.53）；组间差异为-0.31（95% CI，-0.95至0.32），也在不劣性界值1.28以内（P < .001）。两组焦虑下降均超过MCID，且在次要结局上改善相似。
> 
> 研究结论：对于癌症幸存者的焦虑，音乐治疗不劣于CBT。两种远程干预均带来了具有临床意义且持久的焦虑改善。

### 第二部分 AI 大师评价

本研究以随机临床试验比较远程音乐治疗与认知行为疗法在癌症幸存者焦虑管理中的疗效，结果显示音乐治疗在短期及长期内均不劣于CBT。研究样本具有一定代表性，主要终点与MCID设定科学，结论具有临床指导意义。其创新性在于首次以远程形式系统比较两种心理干预的长期效果，但研究人群种族分布不均及远程依从性可能影响推广性。总体而言，该研究为癌症幸存者提供了更具可及性的非药物性焦虑干预选择。

---

## 43. “我不知道”的力量

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41494144)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41494144
**DOI：** 10.1200/JCO-25-02489

### 第一部分 原文与翻译

**英文原标题：** The Power of "I Don't Know".

> **英文摘要：**
> A reflection by @SondosZayedMD on the unexpected power of saying "I don't know"-and how honest uncertainty can deepen trust, guide care, and create space for what truly matters in oncology. #JCO @JCO_ASCO.

> **中文摘要：**
> 本文是 @SondosZayedMD 对于表达“我不知道”这一意外力量的思考——并探讨了真诚的不确定性如何能够深化信任、引导医疗照护，并为肿瘤学中真正重要的事物创造空间。#JCO @JCO_ASCO。

### 第二部分 AI 大师评价

这篇文章以反思随笔的形式，探讨在肿瘤科临床实践中承认“不知道”所蕴含的力量。作者认为，与其掩饰不确定性，不如以诚实态度面对未知，从而促进医患间的信任与理解。文章虽无实证研究，但其思想价值在于关注医学人文与临床决策沟通层面的深意。该反思为临床医师提供了一种面对不确定性的成熟而真实的思维方式。

---

## 44. 多发性骨髓瘤的治疗：ASCO-安大略省健康（癌症护理安大略）动态指南

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41494138)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41494138
**DOI：** 10.1200/JCO-25-02587

### 第一部分 原文与翻译

**英文原标题：** Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

> **英文摘要：**
> PURPOSE: To provide updated guidance regarding the therapy for multiple myeloma.
> 
> METHODS: ASCO and Ontario Health (Cancer Care Ontario) convened a joint Expert Panel and conducted an updated systematic review of the literature.
> 
> RESULTS: The updated review identified a total of 161 relevant randomized trials.
> 
> UPDATED RECOMMENDATIONS: Daratumumab therapy may be offered to patients with high-risk smoldering myeloma. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as initial therapy for transplant eligible patients. They should also be offered at least lenalidomide maintenance, with or without daratumumab, carfilzomib, and/or dexamethasone. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as therapy for suitable transplant-ineligible patients. Patients with relapsed or refractory multiple myeloma should be offered triplet therapy or T-cell redirecting therapies according to a set of recommended principles.Additional information is available at www.asco.org/hematologic-malignancies-guidelines.

> **中文摘要：**
> 研究目的：旨在为多发性骨髓瘤的治疗提供最新指导意见。
> 
> 研究方法：ASCO 与安大略省卫生机构（癌症护理安大略）共同召集了一个专家小组，并进行了系统文献综述的更新。
> 
> 研究结果：更新后的综述共识别出161项相关的随机对照试验。
> 
> 最新推荐意见：可向高危潜伏性骨髓瘤患者提供达雷妥尤单抗治疗。对于符合移植条件的患者，应将含达雷妥尤单抗或伊沙妥昔单抗、硼替佐米、来那度胺和地塞米松的四联方案作为初始治疗。此外，这些患者应至少接受来那度胺维持治疗，可联合或不联合达雷妥尤单抗、卡非佐米和/或地塞米松。对于适合但不符合移植条件的患者，同样推荐使用含达雷妥尤单抗或伊沙妥昔单抗、硼替佐米、来那度胺和地塞米松的四联方案。对于复发或难治性多发性骨髓瘤患者，应依据推荐原则给予三联治疗或T细胞重定向治疗。更多信息可参阅 www.asco.org/hematologic-malignancies-guidelines。

### 第二部分 AI 大师评价

本指南旨在为多发性骨髓瘤提供最新、动态更新的治疗建议。通过系统性综述161项随机对照试验，ASCO 与安大略省卫生机构提出了基于新证据的临床推荐。其核心创新在于明确四联方案（尤其是以达雷妥尤单抗或伊沙妥昔单抗为主）的应用场景，并对移植适应人群、维持治疗及复发难治病例提出细化策略。该指南强化了免疫治疗及细胞定向治疗在MM管理中的地位，但其局限在于部分推荐仍需长期真实世界验证。

---

## 45. 免疫检查点抑制剂与致癌病毒在实体瘤中的疗效

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41493770)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41493770
**DOI：** 10.1158/1078-0432.CCR-25-2846

### 第一部分 原文与翻译

**英文原标题：** Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors.

> **英文摘要：**
> Viral infections are estimated to contribute to 12-20 % of all cancers worldwide, with virus-driven malignancies disproportionately affecting low- and middle-income countries while metabolic and non-viral factors predominate in high-income regions. Key oncogenic viruses that cause solid tumors include high-risk human papillomaviruses (HPV), Epstein-Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8), and Merkel cell polyomavirus (MCPyV). Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by boosting immune responses against tumors. While viral infection-associated tumors often exhibit "hot" immune profiles, clinical outcomes with ICIs remain inconsistent. Some studies report improved survival in virus-associated cancers, whereas others indicate no clear benefit, which might reflect high variability in tumor microenvironments and immune responses. In this review, we aim to explore the direct and indirect contribution of different viruses to carcinogenesis in solid tumors, with a particular focus on immunotherapy effectiveness based on infection status.

> **中文摘要：**
> 据估计，病毒感染约占全球癌症发病的12%至20%，其中由病毒驱动的恶性肿瘤在中低收入国家的负担尤为突出，而代谢及非病毒因素在高收入地区更为常见。导致实体瘤的主要致癌病毒包括高危型人乳头瘤病毒（HPV）、Epstein-Barr病毒（EBV）、乙型肝炎病毒（HBV）、丙型肝炎病毒（HCV）、卡波西肉瘤相关疱疹病毒（KSHV/HHV-8）以及Merkel细胞多瘤病毒（MCPyV）。免疫检查点抑制剂（ICIs）通过增强机体对肿瘤的免疫反应，已深刻改变了癌症治疗的格局。尽管病毒感染相关的肿瘤通常表现出“免疫活跃（热型）”的特征，但ICIs的临床疗效仍不一致。一些研究报告显示病毒相关癌症患者的生存率得到改善，而另一些研究则未发现明确获益，这可能反映了肿瘤微环境及免疫反应的高度差异性。本综述旨在探讨不同病毒对实体瘤致癌过程的直接与间接作用，并重点分析基于感染状态的免疫治疗效果。

### 第二部分 AI 大师评价

本文综述系统探讨了多种致癌病毒在实体瘤形成中的作用，并评估了免疫检查点抑制剂在病毒相关与非病毒相关肿瘤中的差异疗效。研究强调病毒感染可塑造“热型”免疫微环境，但临床获益仍受多因素限制。作者提出了基于感染状态优化免疫治疗策略的思路，具有较高的前瞻性与临床指导意义。局限性在于缺乏统一的临床数据整合及机制验证研究。

---

## 46. 酒精与癌症

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41324932)
**期刊：** JAMA
**PMID：** 41324932
**DOI：** 10.1001/jama.2025.19210

### 第一部分 原文与翻译

**英文原标题：** Alcohol and Cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究发表于《JAMA》，主题聚焦于酒精与癌症之间的关系。虽然该文未提供摘要，但从标题可推测其可能探讨酒精摄入与多种癌症发生风险的流行病学关联及机制基础。文章或包含对现有证据的系统综述，强调公共卫生政策的重要性。局限性可能在于缺乏新实验数据或具体干预分析。

---

## 47. 酒精与癌症——回复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41324920)
**期刊：** JAMA
**PMID：** 41324920
**DOI：** 10.1001/jama.2025.19212

### 第一部分 原文与翻译

**英文原标题：** Alcohol and Cancer-Reply.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文为作者就先前发表的“酒精与癌症”相关研究或评论所作出的回复。从文献类别判断，属于学术讨论性质，旨在澄清或补充原有观点，可能涉及流行病学证据解读或因果推断争议。由于未提供摘要，具体论点和数据细节不可得，但此类回复通常有助于学术界对饮酒与肿瘤风险关系达成更精准共识。

---

速递结束，祝您工作愉快！